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RESUMEN 
 
INTRODUCCIÓN 
El envejecimiento de la población es un proceso que está teniendo lugar en todo el mundo. 
Una de las consecuencias es el aumento de la prevalencia de los problemas crónicos de 
salud y, por lo tanto, también la coexistencia de ellas, denominada comorbilidad o 
multimorbilidad. La multimorbilidad es un problema de salud muy frecuente en todos los 
grupos de edad, y especialmente en las personas mayores. Es un factor pronóstico 
importante, con efectos negativos sobre la mortalidad, los resultados quirúrgicos, las 
complicaciones postoperatorias y la duración de la estancia hospitalaria, y un efecto 
directo e independiente sobre la discapacidad y la calidad de vida. Existen diferentes 
instrumentos para evaluar la multimorbilidad; la elección del instrumento depende del 
contexto del estudio y los resultados de interés. La escala Disease Burden Morbidity 
Assessment (DBMA) es un cuestionario de autovaloración en el que los participantes 
clasifican la carga de la enfermedad causada por una serie de problemas crónicos de salud. 
Fue diseñada y validada para asociarse con resultados centrados en el paciente. Sin 
embargo, todavía no se había realizado una validación siguiendo una metodología 
psicométrica o clinimétrica. 
 
OBJECTIVOS 
Los objetivos de esta tesis fueron validar la DBMA de acuerdo con la Teoría Clásica de los 
Test (TCT) (Estudio 1), evaluar la validez de grupos conocidos, la validez convergente y la 
validez predictiva (Estudio 2) y realizar un análisis Rasch de la escala (Estudio 3).  
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MÉTODOS 
Se utilizaron datos del Estudio Longitudinal Envejecer en España, Estudio Piloto (ELES-
PS), en la que se incluyeron adultos no institucionalizados mayores de 50 años residentes 
en España. En el Estudio 1 y 2, se utilizaron submuestras de personas de 65 años o más. El 
cuestionario CAPI del estudio ELES-PS incluyó la DBMA. En esta escala, que consiste en 
una lista de 21 problemas crónicos de salud, se pregunta a los participantes para cada 
problema crónico de salud si lo tienen y, en caso afirmativo, hasta qué punto interfiere con 
su vida cotidiana en una escala de 1 (nada) a 5 (mucho). La puntuación total, obtenida 
sumando las puntuaciones de todos los problemas crónicos de salud presentes, 
proporciona una medida de la carga de la enfermedad autopercibida.  
 
En el primer estudio, se analizaron las propiedades psicométricas de la escala (viabilidad, 
aceptabilidad, asunciones escalares, fiabilidad y validez de constructo). La 
dimensionalidad fue estudiada con un análisis factorial exploratorio. En el Estudio 2, se 
evaluó la validez de grupos conocidos para sexo y grupos de edad (<75 años frente a ≥75 
años). Para la validez convergente, se utilizó un modelo de regresión lineal multivariante 
para evaluar las diferencias de los resultados de la DBMA en función de la edad y el sexo, la 
salud autopercibida, la función física, la calidad de vida,  el equilibrio afectivo y el uso de 
recursos sanitarios. Para la validez predictiva se estudió la asociación con la mortalidad a 
cuatro años utilizando un modelo de Cox y curvas de Kaplan-Meier. En el análisis Rasch se 
analizaron los siguientes atributos métricos de una manera iterativa: ajuste al modelo 
Rasch, unidimensionalidad, fiabilidad, funcionamiento diferencial de los ítems (DIF), 
independencia local de los ítems y adecuación de la escala de respuesta. Posteriormente, 
se evaluó la validez de constructo de la medida lineal proporcionada por el análisis Rasch. 
 
 
IV 
 
RESULTADOS 
En el análisis TCT, la viabilidad y la aceptabilidad fueron satisfactorias, salvo efectos suelo 
grandes (> 50%) y una distribución asimética (skewness=1,8). La correlación ítem-total 
corregida osciló entre 0,10-0,49, el índice de homogeneidad de los ítems fue de 0,09 y el 
alfa de Cronbach de 0,72. La DBMA  mostró una correlación fuerte con la escala de función 
física (r = -0,56) y la salud autopercibida (r = -0,56), y moderada con la depresión (r = 
0,41) y la calidad de vida (r = -0,41). El análisis factorial exploratorio extrajo 5 factores, 
explicando el 44% de la varianza.  
 
En el análisis de grupos conocidos en el Estudio 2 se encontraron para las mujeres 
prevalencias de enfermedades mayores y también mayor carga de enfermedad por 
enfermedad presente. Las mismas diferencias fueron halladas para los grupos de edad, 
pero fueron menos pronunciadas. En la regresión multivariante, el sexo, la salud 
autopercibida, la función física, la calidad de vida, el equilibrio afectivo y la utilización 
recursos sanitarios se asociaron significativamente con la DBMA. El modelo de Cox mostró 
un hazard ratio de 1,07 y las curvas de Kaplan-Meier mostraron tasas de supervivencia 
más bajas en los participantes con mayores puntuaciones en la DBMA.  
 
En el análisis Rasch, se recodificaron las escalas de respuesta para lograr un ajuste 
adecuado al modelo de Rasch. La fiabilidad (person separation index) fue baja. La escala 
mostró unidimensionalidad y no se encontró dependencia local de respuestas ni DIF 
relevante. El análisis de precisión relativa mostró que la medida lineal discriminaba mejor 
entre los grupos de edad que la puntuación original, pero para el sexo no se encontró 
ninguna diferencia. 
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CONCLUSIONES 
A pesar de algunas limitaciones como la fiabilidad por debajo de los esperado y un efecto 
suelo alto, se encontró apoyo para la validez de la DBMA. Es un cuestionario 
autoinformado que repite la misma pregunta para diferentes problemas crónicos de salud, 
lo que la hace particularmente aplicable en las personas mayores, ya que es fácil de 
entender y se puede rellenar en un corto período de tiempo. En nuestra sociedad 
envejecida, con un número de personas mayores con multimorbilidad cada vez mayor, la 
DBMA puede ser una herramienta útil que ayuda a comprender mejor y mejorar la 
atención de las personas mayores con múltiples enfermedades crónicas. 
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SUMMARY 
 
INTRODUCTION 
Population aging is a process that is taking place all over the world. One of the 
consequences is the increase in the prevalence of chronic conditions, and therefore also 
the co-existence of them, so-called comorbidity or multimorbidity. Multimorbidity is a 
highly prevalent health problem among all age groups, and especially in the elderly. It is an 
important prognostic factor, with well-described negative effects on mortality, surgical 
outcome, postoperative complications, and hospital length of stay, and a direct and 
independent effect on disability and quality of life. Different instruments exist to assess 
multimorbidity, and the choice of instrument depends on the study context and outcomes 
of interest. The Disease Burden Morbidity Assessment (DBMA) is a self-report 
questionnaire in which participants rate the disease burden caused by a number of 
medical conditions. It was designed and validated to be associated with patient-centered 
outcomes. However, a validation following psychometric or clinimetric methodology had 
not been performed yet.  
 
OBJECTIVES 
The objectives of this thesis were to validate the DBMA according to the Classical Test 
Theory(CTT)  (Study 1), to assess known-groups, convergent and predictive validity 
(Study 2) and to perform a Rasch analysis of the scale (Study 3).  
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METHODS 
Data were used from the Ageing in Spain Longitudinal Study, Pilot Survey (ELES-PS), 
which included community-dwelling adults aged 50 years or more living in Spain. In Study 
1 and 2, subsamples of persons aged 65 years and older were used. The CAPI 
questionnaire of the ELES-PS included the DBMA. In this scale, consisting of a list of 21 
chronic medical conditions, participants are asked for every condition whether they have 
it and if so, to what extent it interferes with their everyday life on a scale from 1 (not at all) 
tot 5 (a lot). The total score, obtained by summing the scores given to the different 
conditions, provides a measure of self-reported disease burden. 
 
In the first study, psychometric properties of the scale (feasibility, acceptability, scaling 
assumptions, reliability and construct validity) were analyzed. Dimensionality was 
assessed through an exploratory factor analysis. In Study 2, known-groups validity for sex 
and age groups (< 75 years vs. ≥75 years) was assessed. For convergent validity, a 
multivariate linear regression model was used to evaluate differences in DBMA scores as a 
function of age and sex, perceived health, physical functioning, quality of life, affect balance 
and utilization outcomes. For predictive validity, the association with four-year mortality 
was assessed using a Cox model and Kaplan-Meier curves. In the Rasch analysis, test of fit 
to the Rasch model, reliability, unidimensionality, response dependency, category 
structure, scale targeting and differential item functioning (DIF) were studied in an 
iterative way. Construct validity of the linear measure provided by the Rasch analysis was 
subsequently assessed.  
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RESULTS 
In the CTT analysis, satisfactory feasibility and acceptability were found, except for large 
floor effects (>50%) as well as a skewed distribution (skewness=1.8). Item-total corrected 
correlation ranged 0.10-0.49, item homogeneity index was 0.09, and Cronbach’s alpha was 
0.72. Disease burden correlated strongly with physical functioning (r= -0.56) and 
perceived health (r=-0.56), and moderately with depression (r= 0.41) and quality of life 
(r=-0.41). Exploratory factor analysis extracted 5 factors, explaining 44% of the variance. 
  
The known-groups analysis in Study 2 found higher disease prevalences and also higher 
disease burden per present condition for women. The same differences were found for age 
groups but less pronounced. In the multivariate regression, sex, perceived health, physical 
functioning, quality of life, affect balance and primary/outpatient care utilization were 
significantly associated with the DBMA. The Cox model displayed a hazard ratio of 1.07 
and the Kaplan-Meier curves showed lower survival rates in participants with higher 
DBMA scores.  
 
In the Rasch analysis, items needed to be rescored by collapsing response categories to 
achieve an adequate fit to the Rasch model. Reliability (person separation index) was low. 
The scale was unidimensional and neither response dependency nor relevant DIF were 
found. Relative precision analysis showed that the linear measure discriminated better 
between age groups than the original raw score, but for sex no difference was found. 
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CONCLUSIONS 
Despite some limitations such as reliability below the expected and high floor effects, 
support was found for the validity of the DBMA. It is a self-reported questionnaire that 
repeats the same question for different conditions, which makes it particularly applicable 
in older populations, since it is easy to understand and can be filled out in a short amount 
of time. In our ageing society, with increasing numbers of older people with 
multimorbidity, the DBMA can be applied to better understand and improve care for older 
persons with multiple chronic conditions.  
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1. INTRODUCTION 
 
1.1. POPULATION AGEING 
 
The ageing of populations is a global phenomenon and is taking place in almost all 
countries of the world. This process results from, on the one hand, declining birth rates 
and, on the other, decreasing mortality. This leads to a reduction in the proportion of 
children and an increase of older people in the population.  In 1950, the worldwide 
proportion of older persons (60 years and older) was 8 % (1). This proportion rose to 
almost 12% in the year 2013, and is expected to reach 21% in the year 2050. In developed 
countries, these proportions are even higher, with a proportion of almost 23% in the year 
2013 and a predicted proportion of 32% for the year 2050.  
 
Population aging has important social and economic consequences. The old-age support 
ratios (number of working-age adults per older person in the population) are already low 
in developed countries, and are expected to continue to decrease in the coming decades 
with fiscal pressures on support systems for older persons. Another important 
consequence lies in the prevalence increase of non-communicable diseases and disability 
as populations age (2).  However, the aging of populations also has its positive sides. The 
increased prevalence of non-communicable diseases originates in the positive trend of 
drastically reduced adult mortality. Older persons can increasingly live independently 
until higher ages, and can support themselves economically, even making financial 
contributions to younger family members (1).  
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1.2. CO- AND MULTIMORBIDITY 
 
Not only the prevalence of non-communicable diseases, but also the co-existence of 
conditions, so-called comorbidity or multimorbidity, increases with the process of 
population ageing. Comorbidity can be described as the existence of one of more other 
diseases among persons with one index-disease (3). This definition implies that the main 
interest is on an index condition and the possible effects of other disorders on the 
prognosis of this condition (4). The term multimorbidity also refers to the presence of 
multiple chronic conditions in one person, but without the perspective of a specific index-
disease. Nevertheless, both terms are often used as synonyms, and since the DBMA can be 
applied from both perspectives, we applied both in this study.  
 
Multimorbidity is a highly prevalent health problem among all age groups, and especially 
in the elderly (5–7). In a systematic review, published by Marengoni et al., the prevalence 
in older people ranged from 55 to 98%, and a prevalence of 20-30% was found when the 
whole population was considered (4). However, several problems arise when comparing 
the prevalences found in different studies. Studies included different populations, such as 
primary care or general population, and different methods of data collection were used: 
self-report, medical records or pharmacy database utilization, for example. Also, although 
most studies define the presence of two concurrent chronic diseases as multimorbidity, 
some studies use other definitions, such as the presence of three concurrent conditions. 
Another limiting factor is the number of disorders taken into account when counting the 
number of conditions. When using a larger list of included conditions, studies are more 
likely to find higher prevalences than when using less extended lists. These differences 
may lead to the broad intervals found in systematic reviews about the prevalence of 
multimorbidity (4,8).  
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1.3. MULTIMORBIDITY AS A PROGNOSTIC FACTOR 
 
Multimorbidity is an important prognostic factor.  Is has well-described negative effects on 
mortality, surgical outcome, postoperative complications,  and hospital length of stay 
(LOS) (9), and a direct and independent effect on disability and quality of life (QoL) (10).  
 
1.3.1. MULTIMORBIDITY AND MORTALITY 
 
In a recent systematic review about the relation between multimorbidity and mortality in 
older adults, an overall hazard ratio (HR) of 1.44 was found (11). Also, the number of 
conditions was positively related to mortality, with a HR of 1.20. When comparing to 
individuals without multimorbidity, the risk of death was 1.73 times higher in patients 
with two or more and 2.72 times higher in patients with three or more chronic conditions. 
However, the included studies were very heterogenic and, again, emphasis was made on 
the importance of multimorbidity measurement standardization: in order to make studies 
comparable, a standard methodology should be followed.  
 
1.3.2. MULTIMORBIDITY AND SURGICAL OUTCOMES 
 
Comorbid patients are known to have poorer surgical outcomes than other persons. In a 
study in which the impact of comorbidity on surgical outcomes in laparoscopy-assisted 
distal gastrectomy was assessed (12), comorbidity was found to be related to local 
complications, systemic complications and hospital mortality. In multivariate analysis, an 
odds ratio (OR) of 1.79 was found for local complications and an OR of 2.89 for systemic 
complications. Another study, assessing the influence of comorbidity on surgical outcomes 
in older surgical cancer patients , concluded that patients with comorbidity had more 
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postoperative morbidity and mortality (13). Patients with comorbid conditions were more 
likely to suffer from postoperative infections, cardiac complications and postoperative 
death. Yet, Hewitt et al. (14) who conducted an observations study among older 
emergency general surgical patients, did not find any differences in surgical outcomes 
(LOS, readmissions and mortality) between comorbid and non-comorbid patients, and 
pointed out the importance of not excluding these patients from surgery. Indeed, in the 
previously cited article about surgical outcomes in older surgical cancer patients, 
comorbid participants showed lower resection rates than other patients, especially in 
advanced tumor stages. This leads to poorer survival rates and might be one of the factors 
that plays a role in the higher mortality rate among persons with multiple chronic 
conditions.  
 
1.3.3. MULTIMORBIDITY AND HOSPITAL LENGTH OF STAY 
 
 Different studies show that patients with multiple comorbid conditions have more 
prolonged hospital stays. In a study among hospitalized patients with cancer and febrile 
neutropenia (15), the prevalence of LOS ≥ 10 days increased with the number of comorbid 
conditions: from 11.2% in patients with no comorbidities to 62.3% in patients with five or 
more comorbidities among patients with solid tumors, and from 17.0% to 80.6% in 
patients with lymphomas. Another study performed in patients with acute burn injury 
showed the same pattern: among patients with dementia, peptic ulcer disease and 
diabetes, there was a 60%, 53% and 26% increase in LOS, respectively.  
 
 
 
 
5 
 
1.3.4. MULTIMORBIDITY AND HEALTHCARE UTILIZATION COSTS 
 
LOS is one of the features that determine healthcare utilization costs. However, it is 
expected that overall healthcare use increases in patients with multimorbidity, which was 
confirmed by a study conducted in a primary care population aged over 50 years in 
Ireland (16). The addition of a single chronic condition led to an associated increase in 
primary care consultations, hospital outpatient visits, hospital admissions and total health 
care costs. The latter increased from €760 for zero to €4096 for more than four comorbid 
conditions. A Swiss study performed in an elderly community-dwelling population drew a 
similar conclusion (17): total healthcare utilization costs were 5.5 times higher in persons 
with multiple chronic conditions. Each additional condition was associated with an 
increased cost of 33% and an increase of 3.2 primary care/specialist consultations per 
year. In total, the mean number of consultations per year was 4.4 in non-multimorbid 
persons and 15.7 in multimorbid patients.  
 
1.3.5. MULTIMORBIDITY AND DISABILITY 
 
Several studies have confirmed the association between multimorbidity and disability. 
Garin et al. (18) performed a study about the impact of multimorbidity on disability and 
QoL in a sample aged over 50 years in Spain. All included 11 chronic conditions, except 
hypertension, were statistically associated with disability, and a higher number of chronic 
conditions was associated with greater disability. Depression, anxiety and stroke were 
found to have the greatest impact on functional status. This finding was confirmed by two 
studies performed by Marventano et al. in community-dwelling and institutionalized 
persons aged 65 years and older in Spain, in which dementia and neuropsychiatric 
disorders were found to be most strongly associated with disability (19,20).  St. John et al 
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(21) studied the relationship between multimorbidity, disability, and mortality in 
community-dwelling older adults in Canada. Among persons with no chronic conditions, 
1.1% had moderate to severe impairment, versus 25.3% in persons with seven or more 
conditions.   
 
1.3.6. MULTIMORBIDITY AND QUALITY OF LIFE 
 
Multimorbidity has a negative effect on QoL. Fortin et al. (22) performed a systematic 
review about the relationship between multimorbidity and QoL in primary care. Thirty 
studies were included and all of them found an inverse association between 
multimorbidity and QoL. This association was especially clear between multimorbidity 
and physical domains of QoL. In the above cited study of Garin et al. (18), the same 
association was found for QoL as for disability: all included 11 chronic conditions, except 
hypertension, were statistically related to QoL and a higher number of chronic conditions 
was associated with lower QoL. Depression, anxiety and stroke had the highest negative 
effect on QoL. Forjaz et al. also found mental health disorders to have a great impact on 
QoL in a study in multimorbid persons aged 65 years and older in Spain (OR: 1.83 to 4.27) 
but found an even stronger association for osteoarticular conditions (OR: 3.37 to 5.10) 
(10).  
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1.4. CO- AND MULTIMORBIDITY MEASUREMENT TOOLS 
 
1.4.1. THE CHARLSON COMORBIDITY INDEX 
 
There are different instruments to assess multimorbidity and the choice of instrument 
depends on the type of data available, study population and specific outcome of interest 
(23). The Charlson Comorbidity Index (CCI) is one of the most widely used tool for 
comorbidity risk adjustment (24). It contains 17 disease categories, each with an 
associated weight based on the associated risk of mortality (Table 1). Since its original 
publication in 1987, it has been validated for its ability to predict mortality in various 
disease groups, such as cancer, renal disease, stroke, intensive care and liver disease (25). 
Moreover, it has been adapted and validated to assess system-centered outcomes such as 
healthcare utilization and healthcare costs (26). Data are either obtained through chart 
review, International Classification of Diseases (ICD) diagnosis codes or questionnaires 
(27,28). Recently, Quan et al. published a revision of the CCI, with adapted weights 
according to current disease prognoses (Table 1.1) (25).  
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Table 1.1. Conditions included in the Charlson Comorbidity Index (24), their associated 
weights and the adapted weights as published by Quan et al. (25) 
Assigned weights 
for diseases 
Adapted weights proposed 
by Quan et al. Conditions 
1 0 Myocardial infarct 
1 2 Congestive heart failure 
1 0 Peripheral vascular disease 
1 0 Cerebrovascular disease 
1 2 Dementia 
1 1 Chronic pulmonary disease 
1 1 Connective tissue disease 
1 0 Ulcer disease 
1 2 Mild liver disease 
1 0 Diabetes 
2 2 Hemiplegia 
2 1 Moderate or severe renal disease 
2 1 Diabetes with end organ damage 
2 2 Any tumor 
2 2 Leukemia 
2 2 Lymphoma 
3 4 Moderate or severe liver disease 
6 6 Metastatic solid tumor 
6 4 AIDS 
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1.4.2. ELIXHAUSER´S COMORBIDITY MEASURE 
 
The Elixhauser´s Comorbidity Measure (ECM) is a recent and frequently applied 
comorbidity index (29). The Elixhauser´s comorbidity tool defines 30 comorbidities, the 
17 included in the CCI and 13 new ones (Table 1.2). Administrative data are used to 
identify the conditions and these are treated separately or as a count (30).  The ECM 
seems to be a better risk adjustment tool than the CCI, especially for mortality beyond 30 
days (23,31–33). However, difficulty in terms of feasibility of collecting 30 comorbidities 
might lead investigators to use the latter rather than the ECM.  
 
 
Table 1.2. Comorbidities included in the Elixhauser’s Comorbidity Measure 
Comorbidity 
Congestive heart failure 
Valvular disease 
Pulmonary circulation disorders 
Peripheral vascular disorders 
Hypertension 
Paralysis 
Other neurological disorders 
COPD 
Diabetes uncomplicated 
Diabetes complicated 
Hypothyroidism 
Renal Failure 
Liver disease 
Peptic ulcer excluding bleeding 
AIDS 
Lymphoma 
Metastatic cancer 
Solid tumour without metastasis 
Rheumatoid arthritis/collagen vascular 
diseases 
Coagulopathy 
Obesity 
Weight loss 
Fluid and electrolyte disorders 
Blood loss anaemia 
Deficiency anaemia 
Alcohol abuse 
Drug abuse 
Psychosis 
Depression 
COPD, Chronic Obstructive Pulmonary Disease 
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1.4.3. THE CUMULATIVE ILLNESS RATING SCALE 
 
The Cumulative Illness Rating Scale (CIRS) (34) is a comorbidity index that was adapted to 
be used in geriatric populations by Miller et al. (CIRS geriatrics: CIRS-G) (35). This scale 
rates 14 body systems (Table 1.3) according to a five point severity scale: 0, no problem; 1, 
mild current problem or past significant problem; 2, moderate disability or morbidity; 
requires "first line" therapy; 3, severe or constant significant disability; uncontrollable 
chronic problem; 4, extremely severe (life threatening), end organ failure, severe 
impairment in function. The total score is taken into account as well as the mean severity 
score for the evaluated body systems. The CIRS and CIRS-G seem to be a useful 
comorbidity measures in clinical research due to their structure according to clinically 
relevant body systems (36). 
 
Table 1.3. Body systems included in the CIRS-G 
Body systems 
Heart 
Vascular 
Hematopoietic 
Respiratory 
EENT (eyes, ears, nose, throat, larynx) 
Upper gastrointestinal tract 
Lower gastrointestinal tract 
Liver 
Renal  
Genito-urinary (ureters, bladder, urethra, prostate, genitals) 
Musculoskeletal / integument 
Neurological 
Psychiatric illness 
Endocrine / metabolic 
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1.4.4.THE SELF-ADMINISTERED COMORBIDITY QUESTIONNAIRE 
 
Comorbidity data from medical records or administrative data can be limited, due to poor 
quality of the documentation, lack of recent documentation and under-reporting of pre-
admission conditions not relevant for the admission diagnosis (37). Therefore, obtaining 
information about comorbidity through self-report has gained interest in the past years. 
Studies have shown that patients are generally capable of giving accurate information 
about their current and past medical conditions (37–39). The Self-Administered 
Comorbidity Questionnaire (SCQ) was first published by Sangha et al. (9). It contains 12 
medical conditions, and participants are asked whether they have the condition, and if so, 
whether they receive treatment for it and if it limits their daily activities (Table 1.4).  
Patients can add three additional conditions in an open-ended way. For every positive 
answer, one point is assigned and, as in other comorbidity measures, a total sumscore is 
obtained. The SCQ showed a moderate correlation with the CCI (0.55) and it is more 
related to QoL than the CCI (40).  
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Table 1.4. The Self-Administered Comorbidity Questionnaire (9) 
 Do you have the 
problem? 
Do you receive 
treatment for it? 
Does it limit your 
activities? 
Problem No (0) Yes (1)  No (0) Yes (1) No (0) Yes (1) 
Heart disease N Y N Y N Y 
High blood pressure N Y N Y N Y 
Lung disease N Y N Y N Y 
Diabetes N Y N Y N Y 
Ulcer or stomach disease N Y N Y N Y 
Kidney disease N Y N Y N Y 
Liver disease N Y N Y N Y 
Anemia or other blood 
disease 
N Y N Y N Y 
Cancer N Y N Y N Y 
Depression N Y N Y N Y 
Osteoarthritis, degenerative 
arthritis 
N Y N Y N Y 
Back pain N Y N Y N Y 
Rheumatoid arthritis N Y N Y N Y 
Other medical problems  
(please write in)  
      
 N Y N Y N Y 
 N Y N Y N Y 
 N Y N Y N Y 
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1.5. THE DISEASE BURDEN MORBIDITY ASSESSMENT 
 
The SCQ introduced a new aspect to comorbidity measurement: the impact of comorbidity 
on daily life. Bayliss et al. took a step further: they created a self-report comorbidity 
assessment instrument that not only assesses whether comorbidities limit daily activities, 
but also to what extent they do so (41). They created a list of 23 common chronic 
conditions (Table 1.5), asking participants whether they have each condition, and for each 
present condition, to what extent it interferes with daily life activities, on a scale from 1 
(not at all) to 5 (a lot).  Scores assigned to single conditions are summed in order to get the 
total score, and this measure of disease severity was conceptualized as disease burden. 
There is no clear definition of disease burden, also called burden of ill health (42) in the 
literature. Usually it is defined as ‘the impact of disease events on various dimensions of 
human life, including health’ (43).   
 
Bayliss et al. published four articles about the instrument. In the first one, an initial 
validation was performed in persons aged 65 years an older (41). Sensitivity and 
specificity relative to chart review were calculated, as well as correlations with general 
health status, physical functioning, depression and self-efficacy. Mean sensitivity and 
specificity relative to chart review was 75% and 92%, respectively. The scale showed 
moderate to high correlations with overall health status, physical functioning and self-
efficacy and a low correlation with depression. These correlations were higher for the 
DBMA than for the CCI or the RxRisk score.   
 
In a second paper, Bayliss et al. studied the relationship between barriers to self-
management, including disease burden, and perceived health and physical functioning 
using multivariate regression modeling (44). This analysis was done in comorbid persons 
aged 65 years and older, with at a minimum diabetes, depression and osteoarthritis. 
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Disease burden was significantly associated with both perceived health and physical 
functioning.  
 
In the third article that Bayliss and colleagues published about the scale, a multivariate 
regression was performed with disease burden as the dependent variable (45).  
Biopsychosocial factors and demographic variables were included as independent 
variables, as well as two data-based comorbidity indices (the Quan comorbidity index and 
the chronic disease score, CDS). In this study, the original 23-items list was reduced to 21 
chronic conditions (Table 1.5). The same sample was used as in the second article (44): 
persons aged 65 years and older with at least three chronic conditions. Age, ‘compound 
effects of conditions’ (treatments and symptoms interfering with each other), self-efficacy, 
financial constraints, and physical functioning were found to be significantly associated 
with disease burden. These associations were not affected by the inclusion of the other 
comorbidity measures in the models.  
 
In the fourth article (46), self-reported disease burden, as a subjective measure, was 
compared to morbidity measured using administrative data (CCI) as an objective 
measurement, in the way that both related to patient-reported and utilization outcomes. 
As in their second and third paper(44,45), a sample of adults aged 65 years or more with 
at least three comorbidities was used, but this time the three medical conditions could be 
any of a list of 10 common chronic conditions. Self-reported disease burden was more 
strongly associated with patient-reported outcomes, whereas morbidity measured by 
diagnosis codes showed a stronger association with higher utilization.  
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The disease burden measure was denominated the Disease Burden Morbidity Assesment 
(DBMA) by Poitras et al. (47). They published a paper about the validation of the French 
version of the DBMA (DBMA-Fv) in a primary care setting in patients aged 18 years and 
older in Quebec, Canada. Bayliss´ reduced 21-item list of chronic conditions was used (45), 
and depression was added as a 22nd item(Table 1.5). Sensitivity and specificity relative to 
chart review were assessed as it had been by Bayliss et al. (41), as well as the correlation 
with the CIRS.  Test-retest reliability was assessed by repeating the questionnaire in the 
form of a mail survey two weeks after the first questionnaire. Sensitivity and specificity of 
74% and 92% were found, very similar to those reported by Bayliss and collegues (41). 
Correlations with the CIRS were 0.46 and 0.56 for the first and second surveys, 
respectively. An intraclass correlation coefficient (ICC) of 0.86 was found, indicating high 
test-retest reliability.  
 
The same research team published another paper about the DBMA-Fv. In this study, the 
relation between the DBMA-Fv and literacy was studied, again in a primary care 
population aged 18 years and older (48). In this research, a simplified version of the DBMA 
was used, with only 11 chronic conditions (Table 1.5). Literacy and the DBMA were 
associated in bivariate analyses, but no longer in multivariate analyses when controlling 
for age and family income.  
 
A third study was performed using the DBMA-Fv, also in Quebec, Canada. In this research 
the relation between the DBMA and obstructive sleep apnea (OSA) was assessed (49). 
Patients were recruited from the records of a sleep laboratory and were between 30 and 
75 years old. No relation between OSA in general and the DBMA was found in bivariate 
analysis, but for severe OSA, a positive association was found with disease burden 
measured with the DBMA (OR: 7.33).   
16 
 
Table 1.5: Chronic conditions included in the DBMA 
Chronic Condition 
Bayliss et al. 
(2005) (41) 
Bayliss et al. 
(2009) (45) 
Poitras et al. 
(2012) (47) 
Hudon et al. 
(2012) (48) 
Angina/coronary artery disease  x x x x 
Asthma  x x x x 
Back pain x x x x 
Bronchitis, chronic/COPD  x x x x 
Cancer (within the past 5 yrs)  x x x  
Cholesterol, elevated x x x x 
Colon problem (e.g., diverticulitis, 
irritable bowel) 
x x x  
Congestive heart failure  x x x x 
Depression   x  
Diabetes  x x x x 
Hard of hearing x x x  
Hypertension  x x x x 
Kidney disease  x    
Nerve condition x    
Osteoarthritis x x x x 
Osteoporosis  x x x  
Overweight  x x x x 
Poor circulation (e.g., peripheral 
vascular disease) 
x x x  
Rheumatic disease, other  x x x x 
Rheumatoid arthritis  x x x  
Stomach problem (e.g., gastritis, 
peptic disease) 
x x x  
Stroke  x x x  
Thyroid disorder x x x  
Vision problem x x x  
COPD, Chronic Obstructive Pulmonary Disease 
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1.6. SCALE VALIDATION: CLASSICAL TEST THEORY AND RASCH 
ANALYSIS 
 
1.6.1. SCALE VALIDATION 
 
As explained in the previous chapter, initial validations of the DBMA were performed by 
Bayliss et al. (41,44–46) and Poitras et al (47). Criterion validity relative to chart review 
was assessed (41,47), as well as convergent validity with other self-reported outcomes as 
physical functioning, perceived health and depression (41), test-retest reliability(47) and 
concurrent validity with other comorbidity measures (41,45,47). 
A next step, essential to guarantee the quality of a scale, is to validate it following a very 
precise psychometric or clinimetric methodology (50). This is done by means of the 
statistical analysis of different psychometric attributes, following a set of norms and 
standards based on scientific methods and theories of health measurement. In this sense, 
there are two main approaches: the classical test theory (CTT) and the item response 
theory (IRT), which includes Rasch analysis (51).  
 
1.6.2. CLASSICAL TEST THEORY 
 
CTT is a quantitative approach to test the validity and reliability of a scale. It can be traced 
back to Spearman at the beginning of the 20th century, who introduced the separation of 
an observed score into a true score and an error, and the estimation of the reliability of 
observed scores (52).  CTT assumes that each observed score on a scale is a combination 
of a true underlying score and an unsystematic or random error (51). According to this 
theory, every person has a true score that would be obtained if there were no 
measurement errors. However, the true score is never shown by the scale, only an 
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observed score, which is assumed to be the true score plus some error. The following 
properties are studied in the CTT approach (50,53): 
 
 Feasibility: The applicability of the instrument in the intended context 
 Acceptability: The extent to which the instrument is acceptable in the target 
population. 
 Scaling assumptions: The extent to which single items are related to the total score 
 Reliability: The degree to which the instrument is free of random error: 
o Internal consistency: the extent to which the items measure the same 
construct 
o Reproducibility: Stability of the scores in time or among different 
evaluators 
 Validity: The degree to which the instrument measures the constructs it is 
supposed to measure: 
o Construct validity:  The degree in which the scores of the instrument are 
consistent with hypotheses about the construct 
 Convergent/ Divergent validity 
 Known-groups validity 
 Predictive validity 
o Criterion validity: Relation of the scale with a gold standard 
 Concurrent validity: Relation of the scale with an existing test 
 Dimensionality: the existence or not of subscales (dimensions) within the scale 
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1.6.3. RASCH ANALYSIS 
 
IRT can be traced back to 1927 when the Law of Comparative Judgment was published by 
Louis Thurstone (54). IRT can be described as a measurement model that tries to explain 
the connection between observed item responses on a scale and an underlying construct 
(51). Stochastic models are used to generate statistical estimations of parameters that 
represent the locations of persons and items on a latent continuum (52). 
 
Rasch analysis was born out of the work of Georg Rasch, a Danish mathematician, in the 
1960s (55). The Rasch model assumes that there is a logistic function of the difference 
between the item difficulty and the person’s ability , or in other words, the level of the 
construct being measured and the person’s level of the construct  (56). It is based on two 
basic assumptions: local independence and unidimensionality. Rasch analysis is 
considered by some authors as a standard for developing new instruments and assessing 
the quality of existing ones (57). It provides a linear measure, which, given an appropriate 
distribution, permits the use of parametric statistics (58).   
 
The key difference between Rasch analysis and CTT is that the latter describes a set of 
data, whereas Rasch analysis aims to obtain data that fit the Rasch model (52). Rasch 
analysis includes the following evaluations (59):  
 
 Fit to the Rasch model: The extent to which the data coincide with theoretical item 
performance according to the Rasch model 
 Reliability: The degree to which the instrument is free of random error 
 Undimensionality:  Only one construct is measured 
 Response dependency: Are items are linked in such way that the response on one 
item will determine the response on another? 
20 
 
 Category structure: The extent to which the responses to the items are consistent 
with the metric estimate of the underlying construct 
 Scale targeting: An indication of how well targeted the items are for people in the 
sample 
 Differential item functioning (DIF): Do different groups within the sample, despite 
equal levels of the characteristic being measured, respond in a different manner to 
an individual item? 
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2. OBJECTIVES 
 
The objective of this thesis was to perform a validation study of the DBMA. To do so, three 
studies were performed. The first study consists of a validation according to the CTT. 
Furthermore, since construct validity gives important information about potential 
contexts a scale can be applied in, this was assessed more thoroughly in a second study. In 
the third study, a Rasch analysis was performed. This responds to the following objectives: 
 
OBJECTIVE 1:  
To perform an analysis of the psychometric properties of the DBMA according to the 
assumptions of the Classical Test Theory:  
-  Feasibility 
-  Acceptability 
- Scaling assumptions 
-  Reliability 
- Construct validity 
- Exploratory factor analysis 
 
 
OBJECTIVE 2:  
To asses construct validity by studying: 
- Known-groups validity for sex and age groups 
- Convergent validity: the relation between the DBMA, patient-centered outcomes, 
and healthcare utilization 
- Predictive validity: the association with mortality. 
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OBJECTIVE 3:  
To perform an analysis following the Item Response Theory of the DBMA through Rasch 
analysis: 
- Test of fit to the Rasch model 
- Reliability 
-  Unidimensionality 
-  Response dependency 
-  Category structure 
-  DIF 
- Scale targeting 
- CTT analysis of the linear measure 
 
 
The results of these three studies will be published shortly. Study 1 had already been 
published at the moment of this writing (60); the article is added as an appendix to this 
thesis . Study 2 is in process of revision for resubmission in a different journal and Study 3 
was accepted for publication (61) and is also presented as an appendix.   
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3. METHODS 
3.1. STUDY DESIGN AND SAMPLE 
 
Data came from the Ageing in Spain Longitudinal Study, Pilot Survey (Estudio Longitudinal 
Envejecer en España, pilot study, ELES-PS), which included 1747 community-dwelling 
adults aged 50 or more living in Spain (62). In this survey, a representative sample was 
selected on a national geographical basis. For sampling, stratified clusters of census 
sections were randomly selected by autonomous region and municipality, proportionally 
to their population of 50 years and older. Households with a telephone line were selected 
at random from a commercial household telephone directory. Per household, individuals 
aged 50 or more were randomly selected, with post-stratification by sex and age group 
(50-59, 60-69, 70-79 and 80-89 years). Field work was conducted in 2011. 
 
The data in the ELES-PS study were collected in four stages: a telephone questionnaire 
(n=1747), a visit by a trained nurse (n=1531), a computer-assisted personal interviewing 
(CAPI) questionnaire (n=1400), and a self-administered questionnaire (n=1145). DBMA 
data were collected through the CAPI questionnaire, and its 1400 participants formed the 
sample that was used for the current work. 
 
The DBMA was developed to be used in older adults (41). Therefore, Study 1 was 
performed with a subsample of the persons aged 65 years or older that answered the CAPI 
questionnaire (n=707). Because we used the percentage of missing values in the CTT 
approach, persons that did not answer the DBMA (completely) were included. These 82 
persons that had missing values for the DBMA were excluded in Study 2 since they would 
not contribute to the analyses, resulting in a sample of 625 persons. Study 3 was 
performed with the whole study sample (n=1400). However, since analysis with samples 
larger than 300 could result in statistically significant deviations from the Rasch model of 
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otherwise well-fitting items, a random subsample of 300 was taken for the Rasch analysis 
(63–66). 
 
The 1747 participants in the ELES-PS form a representative sample of the Spanish 
population. However, people from the Basque region were overrepresented in the sample.  
Due to the complex design and this overrepresentation, analyses carried out with these 
data base must take into account the design variables as well as the weighing factors, if 
possible. Since neither CTT nor Rasch analysis can be performed correcting for complex 
samples or weights, this was only done in the second study.   
 
The data on mortality from all causes were obtained after a follow-up time of four years, 
and were extracted from the Spanish National Death Index (Índice Nacional de 
Defunciones), which includes all deaths registered in Spain since 1987. Persons were 
searched automatically and manually by full name, sex and date of birth. The register does 
not provide information about the cause of death, only the date of death is provided. 
 
The ELES-PS study was approved by the Ethics Committee of the Spanish National 
Research Council. Informed consent was obtained from all individual participants included 
in the study. Since obtaining mortality data from the Spanish National Death Index was not 
among the initial objectives of the ELES study, a second approval was obtained from the 
Ethics Committee of the Institute of Health Carlos III for Study 2.  
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3.2. ASSESSMENTS 
 
3.2.1. THE DBMA 
 
The DBMA, first described by Bayliss et al. (41), consists of a self-report questionnaire in 
which participants rate the disease burden caused by a number of medical conditions, if 
present. Patients are asked to what extent conditions interfere with daily activities, on a 
five-point scale from 1 (not at all) to 5 (a lot). Conditions not present are scored zero. As in 
other studies (Table 1.5), the original DBMA’s 23-item list was adapted by selecting 21 
common chronic conditions based on the conditions used in other multimorbidity indices 
(9,41,67–69). From the multimorbidity indices for which in the validation studies analysis 
per chronic condition had been performed, those conditions that specifically predicted 
mortality, hospitalization or future handicaps and those that showed a transversal 
association with physical functioning were selected (67–69).  In case analysis per 
condition had not been performed, all conditions included in these multimorbidity indices 
were selected (9,41). As a criterion, only conditions selected from more than one index 
were included. A few exceptions were made: liver diseases were not included because of 
their low prevalence in older adults; and urinary tract conditions, anxiety and memory 
related disorders were added because of their high prevalence in this population. The 
DBMA, as used in the ELES-PS study, is shown in Table 3.1.  
 
The DBMA is a measure of disease burden but can also be applied as a disease count, since 
it asks for the presence of 21 chronic conditions. Other authors applied the scale for this 
purpose (70) and so did we in one of the analyses in Study 1. However, in the present 
work, when using the term ‘DBMA score’ it always refers to disease burden, unless stated 
otherwise.  
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Table 3.1. The DBMA as used in the ELES-PS study 
  In case of an affirmative answer, 
ask:   
  Do you have 
the condition? 
On a scale of 1 to 5, can you tell me 
whether the condition has limited 
you in your usual activities? 
  Yes/No 1 (not at all) 2 3 4 5 (a lot) 
1 Hypertension 1        2 1     2     3     4    5 
2 Myocardial infarction 1        2 1     2     3     4    5 
3 Heart failure 1        2 1     2     3     4    5 
4 Angina 1        2 1     2     3     4    5 
5 Circulation problems/ 
intermittent claudication 
1        2 1     2     3     4    5 
6 Osteoarthritis 1        2 1     2     3     4    5 
7 Rheumatoid arthritis 1        2 1     2     3     4    5 
8 Asthma 1        2 1     2     3     4    5 
9 COPD/emphysema 1        2 1     2     3     4    5 
10 Diabetes 1        2 1     2     3     4    5 
11 Gastric/duodenal ulcer 1        2 1     2     3     4    5 
12 Kidney disease 1        2 1     2     3     4    5 
13 Depression 1        2 1     2     3     4    5 
14 Anxiety 1        2 1     2     3     4    5 
15 Cerebral 
embolism/stroke 
1        2 1     2     3     4    5 
16 Cancer 1        2 1     2     3     4    5 
17 Osteoporosis 1        2 1     2     3     4    5 
18 Memory disorders 1        2 1     2     3     4    5 
19 Parkinson's disease 1        2 1     2     3     4    5 
20 Chronic back pain 1        2 1     2     3     4    5 
21 Urinary tract problems 
(prostate, bladder) 
1        2 1     2     3     4    5 
COPD, Chronic Obstructive Pulmonary Disease 
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3.2.2. OTHER ASSESSMENTS 
 
To screen for depression, the self-administered questionnaire of the ELES-PS included the 
dichotomous 10-item Center for Epidemiologic Studies Depression Scale (CES-D) (71). It 
contains 10 questions with 'yes/no' response categories, asking about the feelings of the 
respondent in the past week (Table 3.2). A score of 1 is assigned to every positive answer 
for depression. A sum score of 3 was used as a cut-off point for depression (72). Previous 
studies found support for this short version of the CES-D to be as reliable as the original 
CES-D, with a Cronbach´s alpha of 0.80, and to show satisfactory convergent validity with 
the Composite International Diagnostic Interview (sensitivity and specificity of 84% and 
64%, respectively) (71,72).  
 
Table 3.2. The Center for Epidemiological Studies Depression Scale, 10-item version (71) 
 
 
 yes no 
I felt depressed 1 0 
I felt that everything I did was an effort 1 0 
My sleep was restless 1 0 
 I was happy 0 1 
I felt lonely 1 0 
People were unfriendly 1 0 
I enjoyed life 0 1 
 I felt sad 1 0 
I felt that people disliked me 1 0 
I could not get going 1 0 
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QoL was assessed through the Personal Wellbeing Index (PWI) (73), which provides a 
measure of general QoL or wellbeing. The PWI was included in the CAPI-questionnaire. 
Respondents are asked to grade, on a scale of 1 to 10, their satisfaction with 7 life 
dimensions: standard of living, personal health, achieving in life, personal relationships, 
personal safety, community-connectedness and future security. Total subscores were 
lineally transformed into a 0-100 scale (58), and higher total scores indicate better QoL. 
Previous research found support for the validity and reliability of this linear measure in 
older adults, correlating moderately with 'satisfaction with life' and showing a person 
separation index (PSI) of 0.91 (58). 
 
The CAPI questionnaire included a question about perceived health, asking the 
participants to grade their satisfaction with their health status on a scale from 1 (very bad) 
to 5 (very good). This variable was used in Study 2, and dichotomized into very good/ 
good vs. acceptable/poor/very poor (74). However, the PWI also includes a dimension 
about personal health answered on a 0-10 rating scale. Because of this broader response 
scale, this dimension was used as a measure of perceived health in Studies 1 and 3.  
 
A 24-item list of different basic and instrumental activities of daily living, as used in the 
Health and Retirement Study (75), was included in the CAPI questionnaire as a measure of 
physical functioning (Table 3.3). Included activities are getting dressed, walking 100 
meters and making phone calls, among others. Participants were asked whether they 
experienced difficulties in performing them, on a scale from 1 (always) to 4 (never). Scores 
were summed to get a measure of physical functioning.  In Study 2, this variable was 
dichotomized into no disability (score of 96, which was the maximum score) vs. any level 
of disability (scores <96)(10).
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Table 3.3. The 24-item list of different basic and instrumental activities of daily living as 
included in the ELES-PS CAPI questionnaire 
 
Do you have any difficulty with… Always Sometimes Almost 
never 
Never 
1 Walking 100m 1 2 3 4 
2 Walking 1000m 1 2 3 4 
3 Sitting for about two hours 1 2 3 4 
4 Getting up from a chair after sitting for long 
periods     
1 2 3 4 
5 Climbing several flights of stairs without 
resting 
1 2 3 4 
6 Climbing one flight of stairs without resting 1 2 3 4 
7 Stooping, kneeling, or crouching 1 2 3 4 
8 Reaching or extending your arms above 
shoulder level 
1 2 3 4 
9 Pulling or pushing large objects like a living 
room chair 
1 2 3 4 
10 Lifting or carrying weights over 10kg, like a 
heavy bag of groceries 
1 2 3 4 
11 Picking up a 5 cents coin from a table 1 2 3 4 
12 Dressing, including putting on shoes and socks 1 2 3 4 
13 Walking across a room 1 2 3 4 
14 Bathing or showering 1 2 3 4 
15 Eating, such as cutting up your food 1 2 3 4 
16 Getting in or out of bed 1 2 3 4 
17 Using the toilet, including getting up and down 1 2 3 4 
18 Using a map to figure out how to get around in 
a strange place 
1 2 3 4 
19 Preparing a hot meal 1 2 3 4 
20 Shopping for groceries 1 2 3 4 
21 Making phone calls 1 2 3 4 
22 Taking medications 1 2 3 4 
23 Work around the house or yard 1 2 3 4 
24 Managing your money, such as paying your 
bills and keeping track of expenses 
1 2 3 4 
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The CAPI questionnaire contained the Scale of Positive and Negative Experience (SPANE) 
to assess affect balance. (Table 3.4) (76). This 12-item questionnaire includes six items 
that assess positive feelings and six items for negative feelings. Respondents are asked to 
report how much they experienced each feeling in the past month, on a scale from 1 (very 
rarely or never) to 5 (very often or always). Scores for negative feelings are subtracted 
from the positive feeling total score, resulting in a total scale from -24 (unhappiest) to 24 
(happiest) to obtain a measure of affect balance. Diener et al (76) found support for the 
validity and reliability of the scale,  converging well with other measures of emotions and 
affective well-being, and showing a Cronbach´s alpha of 0.88.  
 
Table 3.4. The Scale of Positive and Negative Experience as used in the ELES-PS (76) 
 
 Very Rarely 
or Never 
Rarely Sometimes Often Very Often 
or Always 
Positive 1 2 3 4 5 
Negative 1 2 3 4 5 
Good 1 2 3 4 5 
Bad 1 2 3 4 5 
Pleasant 1 2 3 4 5 
Unpleasant 1 2 3 4 5 
Happy 1 2 3 4 5 
Sad 1 2 3 4 5 
Afraid 1 2 3 4 5 
Joyful 1 2 3 4 5 
Angry 1 2 3 4 5 
Contented 1 2 3 4 5 
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Two measures were included in the CAPI questionnaire to assess the use of healthcare 
resources. In the first, the numbers of visits in the past month to the primary care center 
(general practitioner, nurse), physiotherapist or medical specialist were summed, to get a 
measure of primary and outpatient care utilization. To assess the use of hospital care 
resources, the visits to the emergency department, ‘day hospital’ and hospital admissions 
in the past year were summed. Both variables were dichotomized, into use vs. no use of 
healthcare resources in the corresponding period of time.  
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3.3. STATISTICAL ANALYSES 
 
Statistical analyses were performed in Stata 12 for Windows, unless stated otherwise.  
 
3.3.1. STATISTICAL ANALYSIS IN STUDY 1: CTT 
 
The following psychometric properties were examined: feasibility, acceptability, scaling 
assumptions, reliability and construct validity. Feasibility was assessed by determining the 
percentage of missing values per item and the percentage of computable scores for the 
total scale, considering acceptable scores <10% and >90%, respectively (77). Acceptability 
was explored by comparing possible and observed scores and assessing mean-to-median 
difference for the total scale (criterion, <10% of the scale range) as well as floor and 
ceiling effects (<15%) and skewness (-1 to 1) (78). 
 
Scaling assumptions were determined through the item-total corrected correlation (ITCC) 
for each item (criterion r≥0.40) (79). Reliability was assessed through internal consistency 
(Cronbach’s alpha) and the item homogeneity index (criteria: α ≥ 0.70 and r ≥0.30, 
respectively) (77).  
 
For convergent validity, we expected self-reported disease burden to be negatively 
associated with perceived health, physical functioning and QoL and to find a positive 
association with depression (10,80,81). This was calculated through Spearman’s rank 
correlation coefficients due to the non-normal distribution of the DBMA. Correlation 
coefficients were interpreted following Cohen’s conventions, considering correlations ≥0.5 
as large, 0.5-0.3 as moderate and 0.3-0.1 as having a small magnitude (82).  
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Spearman’s rank correlations were repeated using the self-reported number of conditions 
instead of disease burden, to evaluate the added value of assessing the impact of 
conditions on daily life. These correlations were compared using a Fisher r-to-z 
transformation (83). Because the DBMA had a higher number of missing values than the 
disease count variable, those cases with missing values for DBMA were excluded in this 
analysis to make the two variables comparable.  
 
Known-groups validity was examined comparing disease burden by sex and age groups 
(Wilcoxon rank-sum test). Since multimorbidity is more frequent in both women and 
older people, we hypothesized to find significantly higher scores in these groups than in 
men and  younger participants (84). 
 
Dimensionality and factor structure were explored through exploratory factor analysis, 
using a principal axis factoring method with oblimin rotation. The number of extracted 
factors was determined according to eigenvalues (>1) and visual inspection of the 
screeplot, taking the 'elbow' as the point of separation (85).  
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3.3.2. STATISTICAL ANALYSIS IN STUDY 2: CONSTRUCT VALIDITY 
 
Due to overrepresentation of the Basque Country in the sample, analyses were weighted 
to the underlying population distribution and accounted for the effect of stratification and 
clustering. Therefore, descriptive statistics are presented with are presented with 
standard errors (SE) instead of standard deviations (SD). Not all statistics allowed the 
correction for the complex design or weights; for those cases where correction was not 
possible, this is stated in the text.  
 
In Study 1, known-groups validity was assessed by sex and age group (<75 years vs. ≥75 
years). In Study 2, this was studied for disease prevalence and disease burden scores 
separately. First, differences in the mean number of present conditions per person were 
studied by sex and age group. Since the Wilcoxon rank-sum test does not allow weights or 
correction for complex design, p-values for the differences in the mean number of present 
conditions were obtained through a Somers’ D analysis (86) weighted for the population 
distribution. Furthermore, an analysis of the differences in disease prevalence and disease 
burden scores was performed for single conditions. Significance of the differences in 
disease prevalence by groups was assessed with Chi-square tests, whereas significance of 
the difference in disease burden scores was tested with Somers’ D tests.  
 
Study 1 assessed convergent validity with perceived health, physical functioning, QoL and 
depression. These variables were included in the convergent validity assessment in study 
2 as well, except for depression, which was excluded because of a very high proportion of 
missing values (24.5%).  Affect balance and the use of healthcare utilization were added 
since we expected them to be related to the DBMA as well (46,87). 
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Bivariate linear regression models were used to determine which of the following 
independent variables should be included in the multivariate linear regression model: 
age,sex, patient-centered variables (perceived health, physical functioning, QoL, affect 
balance) and system-centered outcomes (primary/outpatient care and hospital care use). 
Likelihood ratio statistics were applied beforehand to decide whether variables should be 
used as continuous, categorical or dichotomic variables: age, QoL and affect balance were 
used as continous variables and perceived health, physical functioning and the use of 
outpatient and hospital care were dichotomized. 
 
Independent variables that were significant at a p≤0.15 level  in the bivariate analysis 
were considered for inclusion in the multivariate model (45). Because of the skewed 
distribution of the DBMA in our sample, a generalized linear model with gamma 
distribution and log link was used for the bivariate and multivariate regression models.  
 
For variables that were significant in the bivariate analysis and no longer in the 
multivariate regression, confounding factors were assessed to investigate which variables 
caused this change in significance. This was done by adding potential confounding 
variables individually to the bivariate models of the non-significant variables. A change-in-
estimate (CIE) criterion of 20% was used (88). In order to be considered as a confounder, 
variables should be associated with both the independent and the dependent variable. 
Associations with the independent variable were studied with linear regression models 
(regression coefficient).  
 
This study used the Cox proportional hazards model to examine the performance of the 
DBMA as a predictor of survival, after adjusting for age and sex. The proportional hazards 
assumption was confirmed graphically. Besides, the comparison of survival between three 
DBMA categories (low, medium and high) was done using Kaplan-Meier curves, taking as 
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low DBMA the scores within the first quartile in the used sample (≤2) and as high the 
scores within the last quartile (≥11). This analysis does not allow correction for complex 
samples, so only the weights were taken into account.  
 
A logistic regression model, with mortality as a dependent variable and DBMA as an 
independent variable, adjusted for age and sex, was used to calculate a Receiver Operating 
Characteristic (ROC) curve. The area under the ROC curve (AUC) was used to assess how 
well the DBMA predicted mortality, with the following cut-off points: non-predictive (AUC 
=0.5), less predictive (0.5<AUC<0.7), moderately predictive (0.7≤AUC<0.9), highly 
predictive (0.9≤AUC<1) and perfect prediction (AUC =1) (89).  
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3.3.3. STATISTICAL ANALYSIS IN STUDY 3: RASCH ANALYSIS 
 
The Rasch model is a mathematical expression that assumes that a response is a logistic 
function of the difference between the item difficulty and the respondent’s ability (55). In 
our case, item difficulty refers to the level of disease burden measured by the item on the 
constructs continuum, whereas the respondent’s ability reflects how much burden a 
person experiences. 
 
Rasch analysis was performed using RUMM 2030 (90). Differences between thresholds 
were not expected to be equal across items, so the Masters’ Partial Credit polytomous 
model was chosen (91), which was confirmed by a significant likelihood ratio statistic. 
Test of fit to the Rasch model, reliability, unidimensionality, response dependency, 
category structure, DIF and scale targeting were studied (59). These parameters were 
assessed in an iterative way, making model modifications until an adequate fit was 
achieved. 
 
Fit to the Rasch model was tested by comparing the observed data with the theoretical 
item performance according to the Rasch model. The item-trait interaction statistic, 
reported as a chi-square, needs to be non-significant (59). Item and person summary fit 
statistics should follow a normal distribution with a mean and SD of 0 and 1, respectively.  
Individual item and person fit residuals should be within the ±2.5 range and chi-square 
differences for items and persons should be non-significant with Bonferroni correction for 
number of items (92).  
 
Reliability was determined with the person separation index (PSI), which is interpreted 
similarly to Cronbach´s coefficient alpha: a minimum value of 0.70 for group comparisons 
is recommended and 0.90 for person comparisons (59). The PSI was also obtained in 
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RUMM2020 since algorithms derived from this program provide reliability results less 
influenced by extreme values, missing data, and floor and ceiling effects than those 
obtained with RUMM2030 (93). 
 
Unidimensionality was tested through a Principal Component Analysis (PCA) of the 
residuals (94). This analysis defines two subsets of items, positively and negatively 
correlated with the first residual factor, and the differences in these estimates for each 
person are compared with a t-test. The differences in estimates are supposed to be 
normally distributed, so the percentage of these tests outside the range of -1.96 to 1.96 
should not exceed 5% in a binomial test (59). 
 
Response dependency was assessed through the residual correlation index and a 
correlation of > 0.30 was taken as an indication of local dependency (58). This can be 
illustrated with the following example (59): if you include two walking items in a scale, 
one asking if a person can walk a kilometer without difficulty, and one asking if a person 
can walk 100 meters, a person that can walk one kilometer will always answer that he or 
she can walk 100 meters as well.  Related items should be combined in a subtest, so in the 
example above, one walking item could be made with response items relative to the 
walking distance.  
 
Response category structure was explored through category probability curves, and in 
case of disordered thresholds, items were rescored by collapsing adjacent categories. A 
threshold is the point of equal response probably between two adjacent response 
categories. 
 
DIF examines whether different groups within the sample, despite of equal levels of the 
characteristic being measured, respond in a different manner to an individual item (95). 
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DIF was studied for age (< 65 years vs. ≥65 years, 65 was the median value in our sample), 
sex and educational level (primary school or less vs. more than primary school). The DIF 
analysis was done through an analysis of variance (ANOVA) with Bonferroni correction. In 
case DIF was identified, this was further analyzed through a top-down purification 
approach (95).  In this approach, items are divided into two groups, according to the 
presence of absence of DIF, and two testlets (or superitems) are created. If the testlet 
formed by the items with DIF does not present DIF itself, then it is considered to cancel out 
(96). 
 
Scale targeting was assessed to analyze whether the sample and items covered all levels of 
the construct continuum. This was done through visual inspection of a graphic showing 
the distribution of persons and items along the construct.  
 
Once fit to the Rasch model was achieved, disease burden scores of the total sample were 
used to calculate a linear measure, on a logit scale, which was converted into a 0-47 range 
using a linear transformation. In order to compare the subsample of 300 and the rest of 
the sample (n=1100), a paired-sample t-test was done, comparing the logit estimation of 
the two samples (300 vs. 1100) for each raw-score. Anchor values of the sample of 300 
were used to fix item estimations of the other sample. In addition, a DIF analysis by sample 
(300 vs. 1100) was performed. 
 
Psychometric attributes of the linear measure according to the CTT were analyzed in 
Stata: mean-to-median differences (criterion,<10%), floor- and ceiling effects (<15%) and 
skewness (-1 to 1) were calculated for acceptability (78). Construct validity was assessed 
through known-groups validity for sex and age (<65 years vs. ≥ 65 years) and convergent 
validity with other health outcomes. We hypothesized to find higher disease burden scores 
for women (97) and in the highest age group (98), which was studied with a Wilcoxon 
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rank-sum test due to the non-normal distribution of the linear measure. For convergent 
validity, Spearman’s rank correlations were calculated with physical functioning, 
depression (CES-D total score), QoL (PWI), and perceived health (PWI item 2: personal 
health). Moderate to high correlations (r>0.30) were expected (82).  
 
A relative precision analysis was performed in order to compare the ability of the Rasch-
based score in distinguishing groups relatively to the raw summative-based score (99). 
This was done for sex and age groups (<65 years vs.≥ 65 years). Relative precision was 
calculated as the ratio of pairwise Z statistics (the linear measure Z-statistic divided by the 
raw score Z statistic) (100), and a bootstrap method was applied in order to obtain 
confidence intervals (CI) for relative precision statistics. For each patient group 
comparison, a total of 1000 bootstrap samples (with replacement) were drawn, and F 
statistics and relative precision values were calculated for each resampling. The 25th and 
the 975th estimates of these values were taken as the limits of the 95% CI (101). Rasch 
analysis takes into account observations with missing values when calculating the linear 
measure. In order to be able to calculate the relative precision, the studied sample sizes 
should be equal, thus observations with missing values were excluded in the latter 
analysis. 
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4. RESULTS 
4.1. DESCRIPTIVE STATISTICS OF SOCIODEMOGRAPHIC DATA AND 
APPLIED RATING SCALES 
 
Table 4.1 presents the characteristics of the total study sample (n=1400), the Rasch 
analysis subsample (n=300), and the sample used in Study 1 (n=707). Since the sample 
used in the Rasch analysis is supposed to be comparable with the whole sample, this 
column is presented second, followed by the data of Study 1. 
 
As stated, statistical analyses in Study 2 were corrected for the complex design and 
weighted for the sampling method. Therefore, the results are presented in a separate table 
(Table 4.2). In this table, descriptive statistics of the total sample of Study 2 are presented, 
as well as the sample used in the multivariate regression and Spanish national data.   
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Table 4.1. Characteristics of the total study sample (n=1400), the Rasch analysis 
subsample (n=300), and the sample of 65 years and older (Study 1, n=707) 
 
Total sample 
(n=1400) 
Sample for 
Rasch analysis 
(n=300) 
Sample for 
Study 1 
(n=707) 
Characteristic  n      (%) n      (%) n      (%) 
Sex Men 625 (44.6) 132 (44.0) 304 (43.0) 
 
Women 775 (55.4) 168 (56.0) 403 (57.0) 
Education Less than primary 480 (34.3) 98 (32.7) 365 (51.6) 
 
Primary 313 (22.4) 77 (25.7) 137 (19.4) 
 
Secondary 298 (21.3) 61 (20.3) 83 (11.7) 
 
University 309 (22.1) 64 (21.3) 122 (17.3) 
Living area < 10.000 inhabitants 315 (22.5) 70 (23.3) 133 (18.8) 
 
10.000-100.000 inhabitants 502 (35.9) 103 (34.3) 273 (38.6) 
 
100.000-500.000 inhabitants 385 (27.5) 90 (30.3) 201 (28.4) 
 
> 500.000 inhabitants 198 (14.0) 37 (12.3) 100 (14.1) 
Marital status Single 75 (5.4) 17 (5.7) 31 (4.4) 
 
Married/ living with partner 1014 (72.4) 225 (75.0) 439 (62.1) 
 
Widowed 244 (17.4) 44 (14.7) 211 (29.8) 
 
Divorced/separated 67 (4.8) 14 (4.7) 26 (3.7) 
CES-D† Depression 297 (21.2) 78 (26.0) 159 (22.5) 
  No depression 797 (56.9) 160 (53.3) 366 (51.8) 
  Missing 306 (21.9) 62 (20.7) 182 (25.7) 
Characteristic, range  Mean  ±SD Mean  ±SD Mean ± SD 
Age in years 
 
65.5 ± 10.4 64.96 ± 10.3 74.2 ± 6.6 
PWI, 0-100 74.9 ± 11.1 73.3 ± 12.5 75.3 ± 11.1 
Physical functioning, 24-96 91.1 ± 9.6 90.7 ± 10.1 88.3 ± 11.8 
Satisfaction with health, 0-10 7.2 ± 3.9 6.8 ± 1.9 7.1 ± 5.3 
Self-reported number of conditions, 0-21 2.5 ± 2.3 2.6 ± 2.3 3.2 ± 2.4 
DBMA raw score, 0-105 5.3 ± 6.4 5.4 ± 6.2 6.8 ± 7.1 
CES-D, Center for Epidemiologic Studies Depression Scale; DBMA, Disease Burden Morbidity 
Assessment; PWI, Personal Wellbeing Index; SD, Standard Deviation.  
†cut-off point: 3 out of 10 
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Table 4.2. Characteristics of the study sample in Study 2: total sample, sample included in 
the multivariate regression (MVR), and Spanish national data 
 
Total sample 
(n=625) 
 Sample MVR 
(n=503) 
 National 
data ‡ 
Characteristic n (%)†  n (%)†  (%) 
Sex Men 280 (44.6)  238 (47.0)  (43.0) 
 
Women 345 (55.4)  265 (53.0)  (57.0) 
Education Less than primary 310 (49.8)  245 (48.9)   
 
Primary 126 (20.2)  100 (19.9)   
 
Secondary 73 (10.7)  58 (10.9)   
 
University 116 (19.4)  100 (20.3)   
Living area < 10.000 inhabitants 125 (21.8)  104 (22.0)   
 
10.000-100.000 inhabitants 237 (35.4)  186 (34.7)   
 
100.000-500.000 inhabitants 165 (23.3)  136 (24.7)   
 
> 500.000 inhabitants 98 (19.5)  77 (18.6)   
Marital status Single 29 (4.9)  23 (4.9)   
 
Married/ living with partner 394 (60.8)  329 (63.3)   
 
Widowed 179 (29.3)  135 (28.1)   
 
Divorced/separated 23 (4.2)  16 (3.7)   
Perceived health Very good/good 353 (57.4)  299 (57.1)  (44.2) 
 Acceptable/poor/very poor 262 (42.6)  204 (42.9)  (55.8) 
 Missing § 10       
Functional status No disability 249 (41.8)  221 (43.4)   
 Disability 347 (58.2)  282 (56.6)   
 Missing § 29       
Primary/outpatient care Yes 405 (67.3)  330 (67.6)   
past month No 220 (32.7)  173 (32.4)   
Hospital care past year Yes 171 (29.5)  139 (29.3)   
 No 454 (70.5)  364 (70.7)   
Mortality Living 590 (94.5)  473 (94.0)   
 Deceased 35 (5.5)  30 (6.0)  (12.0) ¶ 
Characteristic, range   n Mean   (SE)         Mean        (SE)  Mean 
Age in years 625 73.9 (0.4)  73.7 (0.4)  75.6 
PWI, 0 - 100 540 75.4 (0.6)  75.5 (0.6)   
SPANE, -24 - 24 622 12.9 (0.3)  13.1 (0.4)   
Self-reported number of conditions, 0-21 625 3.22 (0.1)  3.15 (0.1)   
DBMA, 0 - 105 625 7.5 (0.4)  7.5 (0.4)   
†Unweighted counts and weighted percentages. 
‡ Data obtained from the Spanish Population and Housing Census 2011 (102) and the Spanish 
National Health Survey 2011-2012 (103).  
§ In order to make the columns comparable, missing values were not taken into account when 
calculating percentages 
¶ Expected 4 years mortality proportion in our total sample calculated with national mortality data 
2013 (104). 
 
DBMA, Disease Burden Morbidity Assessment; MVR, Multivariate Regression; PWI, Personal 
Wellbeing Index; SE, Standard Error; SPANE, Scale of Positive and Negative Experience 
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As shown in Table 4.1, mean age in the total sample was 65.5 years and 55.4% were 
women. The mean number of self-reported conditions was 2.5, with a mean DBMA score of 
5.3. The distribution of the DBMA in this sample is shown in Figure 4.1.  DBMA scores 
ranged 0-55 and there was an important floor effect: 253 of participants (18.0%) had a 
DBMA score of 0. In the sample aged 65 years and older (Study 1), the mean age was 74.2 
and it showed a slightly higher percentage of women (57.0%). Among these participants, 
the mean number of conditions was 3.2 and the mean DBMA score was 6.8. The 
distribution in this sample (Figure 4.2) ranged 0-41 and still showed a floor effect (10.6%). 
Many participants had a DBMA score of 4 or less.  
 
The participants in Study 2 were 65 years and older as well. In this subsample, a mean age 
was 73.9 years was found after correction for complex samples (Table 4.2). 55.4% of the 
participants were women. Mean DBMA score was 7.5 and after four years, 35 of the 
participants had died (5.5%, weighted percentage). In the total sample of persons aged 65 
years and older (N=707), although not displayed in the tables, a total of 43 persons had 
died (6.6%, weighted percentage). Of the persons included in the sample of Study 2, 57.4% 
declared to be in good or very good health. In the Spanish National Health Survey, a 
percentage of 44.2% was found. The expected percentage of deceased persons after 4 
years in the sample was 12% according to the estimation made by applying mortality rates 
from the National Statistics Institute to the used sample.  
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Figure 4.1. The distribution of the DBMA in the whole study sample (n=1277) 
 
 
Figure 4.2. The distribution of the DBMA in the sample aged 65 years and older (n=625) 
 
 
0
5
0
1
0
0
1
5
0
2
0
0
2
5
0
N
u
m
b
e
r 
o
f 
re
s
p
o
n
d
e
n
ts
0 20 40 60
DBMA score
0
2
0
4
0
6
0
8
0
N
u
m
b
e
r 
o
f 
R
e
s
p
o
n
d
e
n
ts
0 10 20 30 40
DBMA score
46 
 
4.2. RESULTS OF STUDY 1:  CTT ANALYSIS 
 
4.2.1. FEASIBILITY, ACCEPTABILITY, SCALING ASSUMPTIONS, RELIABILITY 
AND CONSTRUCT VALIDITY 
 
Tables 4.3.1 and 4.3.2 present the prevalence of conditions, disease burden per condition 
and scale validation data in the analysed sample. These analyses were not corrected for 
complex samples so the prevalences of conditions will be discussed in Study 2. All items 
had less than 4% missing responses and there were 88.4% computable scores. The 
observed and possible range was 0-5 for all items, except for Parkinson´s disease (0-4). All 
items had a median score of 0, The median for the total scale was 5, with a mean-median 
difference of 1.7%. For all items, floor effects were above 50% and ceiling effects were 
below 3%. When only studying the present conditions, there was still a floor effect, but 
less pronounced, ranging from 14.1% to 66.8% (Table 4.4). The conditions with the 
highest floor effect when present were hypertension (66.8%), kidney disease (64.3%) and 
gastric/duodenal ulcer (63.9%).  Two conditions showed a ceiling effect when present: 
memory disorders (15.8%) and chronic obstructive pulmonary disease 
(COPD)/emphysema (10.9%). 
 
Skewness was 1.80. ITCC was low for all conditions (range: 0.10-0.49), with only six 
conditions meeting the criterion of ≥0.40: osteoarthritis (0.43), intermittent claudication 
(0.43), rheumatoid arthritis (0.49), chronic back pain (0.45), depression (0.45) and 
anxiety (0.44). Cronbach’s alpha was 0.72, and the item homogeneity index was 0.09.  
 
Data on convergent validity are shown in Table 4.5. The DBMA had a Spearman’s 
correlation of -0.56 with physical functioning and perceived health, -0.41 with PWI and 
0.41 with depression (p<0.001 for all). All correlations were significantly stronger for the 
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DBMA than for the number of diseases. Women had higher mean DBMA scores than men 
(8.4 vs. 4.9, p<0.001). Disease burden scores increased significantly with age with a mean 
score of 6.1 in the <75 years of age group and 7.7 in participants aged 75 years and older 
(p<0.001).  
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Table 4.3. Prevalence of conditions, disease burden per condition and scale validation data in the analysed sample (n=707) 
 
Self-reported conditions 
Self-reported 
disease burden 
 
DBMA scores used for scale validation† 
Medical Condition Missing  (%) 
Condition 
present (%) 
 
Mean  (SD) 
 
Missing  (%) Mean (SD) 
Observed 
range 
Floor  
Effect (%) 
Ceiling 
Effect (%) ITCC 
1 Hypertension 2 (0.3) 339 (48.1)  1.5 (0.9)  19 (2.7) 0.7 (1.0) 0-5 53.2 0.3 0.24 
2 Osteoarthritis 2 (0.3) 328 (46.5)  2.7 (1.2)  22 (3.1) 1.2 (1.6) 0-5 55.0 2.9 0.43 
3 Circulation problems/ 
intermittent 
claudication 4 (0.6) 159 (22.6) 
 
2.2 (1.2) 
 
13 (1.8) 0.5 (1.1) 0-5 78.4 0.6 0.43 
4 Rheumatoid arthritis 7 (1.0) 155 (22.1)  2.8 (1.2)  17 (2.4) 0.6 (1.3) 0-5 79.0 1.7 0.49 
5 Chronic back pain 3 (0.4) 155 (22.0)  2.9 (1.2)  16 (2.3) 0.6 (1.3) 0-5 79.5 1.9 0.45 
6 Depression 5 (0.7) 130 (18.5)  2.4 (1.3)  12 (1.7) 0.4 (1.1) 0-5 82.3 1.0 0.45 
7 Urinary tract problems 
(prostate, bladder) 3 (0.4) 127 (18.0) 
 
2.2 (1.2) 
 
11 (1.6) 0.4 (1.0) 0-5 82.9 0.4 0.29 
8 Osteoporosis 3 (0.4) 119 (16.9)  2.4 (1.3)  9 (1.3) 0.4 (1.0) 0-5 83.8 1.3 0.39 
9 Diabetes 3 (0.4) 109 (15.5)  2.0 (1.1)  13 (1.8) 0.3 (0.8) 0-5 85.7 0.6 0.27 
10 Anxiety 4 (0.6) 92 (13.1)  2.5 (1.3)  14 (2.0) 0.3 (0.9) 0-5 88.2 0.7 0.44 
11 Cancer 11 (1.6) 76 (10.9)  2.0 (1.2)  12 (1.7) 0.2 (0.7) 0-5 89.2 0.1 0.13 
DBMA, Disease Burden Morbidity Assessment; ITCC, Item-Total Corrected Correlation; SD, Standard Deviation 
†Self-reported disease burden scores including value 0 if condition not present 
Items are presented in descending order of prevalence
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Table 4.3.  Prevalence of conditions, disease burden per condition and scale validation data in the analysed sample (n=707) continued 
 
Self-reported conditions 
Self-reported 
disease burden  
 
DBMA scores used for scale validation† 
Medical Condition Missing  (%) 
Condition 
present (%) 
 
Mean  (SD) 
 
Missing  (%) Mean (SD) 
Observed 
range 
Floor  
Effect (%) 
Ceiling 
Effect (%) 
ITCC 
12 Gastric/duodenal ulcer 6 (0.8) 74 (10.6)  1.7 (1.1)  8 (1.1) 0.2 (0.6) 0-5 89.7 0.3 0.17 
13 Heart failure 4 (0.6) 74 (10.5)  2.4 (1.4)  14 (2.0) 0.2 (0.8) 0-5 90.8 0.9 0.15 
14 Kidney disease 6 (0.8) 60 (8.6)  1.7 (1.1)  10 (1.4) 0.1 (0.5) 0-5 92.0 0.1 0.19 
15 COPD/emphysema 5 (0.7) 56 (8.0)  2.5 (1.4)  6 (0.8) 0.2 (0.1) 0-5 92.2 0.9 0.19 
16 Asthma 6 (0.8) 41 (5.9)  2.6 (1.3)  8 (1.1) 0.1 (0.7) 0-5 94.4 0.3 0.23 
17 Angina 5 (0.7) 36 (5.1)  2.0 (1.2)  9 (1.3) 0.1 (0.5) 0-5 95.4 0.1 0.16 
18 Myocardial infarction 5 (0.7) 32 (4.6)  2.9 (1.2)  9 (1.3) 0.1 (0.6) 0-5 96.0 0.3 0.10 
19 Cerebral 
embolism/stroke 
4 (0.6) 29 (4.1)  2.0 (1.4)  7 (1.0) 0.1 (0.5) 0-5 96.3 0.3 0.16 
20 Memory disorders 4 (0.6) 26 (3.7)  2.6 (1.4)  11 (1.6) 0.1 (0.5) 0-5 97.3 0.4 0.17 
21 Parkinson's disease 3 (0.4) 12 (1.7)  2.7 (1.3)  5 (0.7) 0.0 (0.3) 0-4 98.6 0 0.16 
 Total         82 (11.6) 6.8 (7.1) 0-41 10.6 0  
COPD, Chronic Obstructive Pulmonary Disease; DBMA, Disease Burden Morbidity Assessment; ITCC, Item-Total Corrected Correlation; SD, Standard Deviation 
†Self-reported disease burden scores including value 0 if condition not present 
Items are presented in descending order of prevalence
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Table 4.4. Missing data, floor and ceiling effects when conditions present 
Condition 
Condition 
present 
DBMA data 
present 
DBMA data 
missing (%) 
Observed 
range 
Floor 
effect (%) 
Ceiling 
effect (%) 
Hypertension 
339 322 17 (5.0) 1-5 66.8 0.6 
Osteoarthritis 
328 308 20 (6.1) 1-5 22.4 6.5 
Circulation problems/ 
intermittent claudication 
159 150 9 (5.7) 1-5 42.0 2.7 
Rheumatoid arthritis 
155 145 10 (6.4) 1-5 20.7 8.3 
Chronic back pain 
155 142 13 (8.4) 1-5 14.1 9.2 
Depression 
130 123 7 (5.4) 1-5 33.3 5.7 
Urinary tract problems 
(prostate, bladder) 
127 119 8 (6.3) 1-5 41.2 2.5 
Osteoporosis 
119 113 6 (5.0) 1-5 31.9 8.0 
Diabetes 
109 99 10 (9.2) 1-5 43.4 4.0 
Anxiety 
92 82 10 (10.9) 1-5 29.3 6.1 
Cancer 
76 75 1 (1.3) 1-5 52.0 1.3 
Gastric/duodenal ulcer 
74 72 2 (2.7) 1-5 63.9 2.8 
Heart failure 
74 64 10 (13.5) 1-5 37.5 9.4 
Kidney disease 
60 56 4 (6.7) 1-5 64.3 1.8 
COPD/emphysema 
56 55 1 (1.8) 1-5 41.8 10.9 
Asthma 
41 39 2 (4.9) 1-5 28.2 5.1 
Angina 
36 32 4 (11.1) 1-5 50.0 3.1 
Myocardial infarction 
32 28 4 (12.5) 1-5 14.3 7.1 
Cerebral 
embolism/stroke 
29 26 3 (10.3) 1-5 57.7 7.7 
Memory disorders 
26 19 7 (26.9) 1-5 21.0 15.8 
Parkinson's disease 
12 10 2 (16.7) 1-4 20.0 0.0 
COPD, Chronic Obstructive Pulmonary Disease 
Items are presented in descending order of prevalence 
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Table 4.5. Convergent validity: Spearman’s rank correlation coefficients of the self-
reported number of conditions and DBMA with other health-related measurements 
 
Number of 
conditions  DBMA 
p-level for 
correlation 
difference  
Depression (CES-D) 
n= 474 0.35*  0.41*  0.0043 
Physical functioning 
n= 596 -0.51*  -0.56*  0.0010 
Quality of life (PWI) 
n= 540 -0.35*  -0.41*  0.0006 
Perceived health   
n= 625 -0.51*  -0.56*  0.0035 
*p <0.001. DBMA, Disease Burden Morbidity Assessment 
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4.2.2. FACTOR ANALYSIS 
 
According to the screeplot (Figure 4.3), the exploratory factor analysis extracted 5 factors. 
Factor loadings >0.3 were considered to be included in the factors, although in the case of 
stroke, a slightly lower value was accepted due to its clear connection with one of the 
factors (Table 4.6). The following factors were found: 
 Factor 1: conditions of the locomotor system (intermittent claudication, arthrosis, 
arthritis, osteoporosis and chronic back pain) 
 Factor 2: depression/anxiety 
  Factor 3: cardiovascular diseases (myocardial infarction, heart failure, angina, 
stroke) 
 Factor 4: mixed group of cancer and renal/urinary tract diseases (kidney disease, 
cancer, urinary tract problems). 
 Factor 5: lung disorders (asthma, COPD) 
Five conditions did not fit in any of the factors: hypertension, diabetes, gastric/duodenal 
ulcer, memory disorders and Parkinson’s disease. The explained variance was 43.6%. 
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Figure 4.3. Screeplot of the 21 DBMA items 
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Table 4.6. Rotated factor loadings 
Item Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Uniqueness 
1 Hypertension 0.05 0.25 0.11 0.16 0.15 0.88 
2 Myocardial infarction 0.02 -0.08 0.55 -0.01 -0.05 0.69 
3 Heart failure 0.04 0.00 0.53 0.01 0.01 0.71 
4 Angina 0.00 0.10 0.54 0.00 0.16 0.68 
5 Circulation problems/ 
intermittent 
claudication 
0.41 0.20 0.15 0.10 0.04 0.75 
6 Osteoarthritis 0.65 0.09 -0.01 -0.04 -0.04 0.57 
7 Rheumatoid arthritis 0.65 0.10 0.07 -0.02 0.01 0.56 
8 Asthma 0.01 0.27 0.04 0.06 0.48 0.69 
9 COPD/emphysema 0.01 0.13 0.08 0.09 0.50 0.72 
10 Diabetes 0.16 0.19 0.09 0.07 0.02 0.93 
11 Gastric/duodenal ulcer 0.20 0.07 -0.01 0.08 -0.02 0.95 
12 Kidney disease 0.05 0.16 -0.03 0.43 0.02 0.78 
13 Depression 0.24 0.64 0.04 0.06 0.02 0.53 
14 Anxiety 0.29 0.59 -0.04 -0.01 0.15 0.55 
15 Cerebral 
embolism/stroke 
0.05 0.15 0.29 0.03 -0.15 0.87 
16 Cancer 0.06 -0.11 -0.03 0.37 0.04 0.84 
17 Osteoporosis 0.46 0.16 -0.01 0.06 0.08 0.76 
18 Memory disorders 0.07 0.04 -0.05 0.16 0.10 0.96 
19 Parkinson's disease 0.11 0.06 -0.03 0.08 0.18 0.95 
20 Chronic back pain 0.54 0.17 -0.08 0.18 -0.02 0.64 
21 Urinary tract problems 
(prostate, bladder) 
0.15 0.10 0.05 0.47 0.13 0.72 
COPD, Chronic Obstructive Pulmonary Disease 
Factor loadings in bold are those included in each of the factors: Factor 1, locomotor system; Factor 
2, depression/anxiety; Factor 3, cardiovascular diseases; Factor 4, cancer and renal/urinary tract 
diseases; Factor 5, lung disorders. 
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4.3. RESULTS OF STUDY 2: CONSTRUCT VALIDITY 
 
4.3.1. KNOWN-GROUPS VALIDITY BY SEX  
 
Table 4.7.1 and 4.7.2 show the prevalences and mean disease burden scores per condition 
and by sex, for the total sample used in this study. Hypertension was the most frequent 
chronic health condition (n=297, 50.7%), and also the condition with the lowest mean 
disease burden score (mean score 1.6, SE=0.1). Parkinson’s disease was the least frequent 
condition (n=8, 1.4%), and the condition with the highest mean disease burden score (3.0, 
SE=0.6), followed by chronic back pain (2.9, SE=0.2) and rheumatoid arthritis (2.9, 
SE=0.1).  
 
Among men, hypertension was also the most frequent condition (n=130, 52.3%), but the 
lowest disease burden score was for gastric/duodenal ulcer (1.6, SE=1.3). Highest scores 
were found for asthma (3.0) (no SE provided in Stata because of a very low prevalence).  
 
Among women, osteoarthritis was de condition with the highest prevalence (n=210, 
64.8%). As in the total sample, hypertension was the condition with the lowest mean 
disease burden score (1.5, SE=0.1). The highest mean score was found for myocardial 
infarction (3.1).  
 
Women had a mean number of chronic conditions of 3.76, men a mean number of 2.56 (p-
value for the difference <0.001). Seven conditions were significantly more prevalent 
among women than in men: circulation problems, osteoarthritis, rheumatoid arthritis, 
depression, anxiety, osteoporosis, and chronic back pain. Five conditions were 
significantly more prevalent in men than in women: myocardial infarction, COPD, diabetes, 
cancer and urinary tract problems.  For disease burden scores per present condition, five 
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significant differences were found, all with higher scores among women. This was the case 
for circulation problems, osteoarthritis, rheumatoid arthritis, diabetes and urinary tract 
problems.  
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Table 4.7. Prevalences and mean disease burden scores per condition and sex in the studied sample (n=625): men (n=280) vs. women (n=345) 
 
 Prevalence†  Disease burden score  
 Total sample Men Women Difference Total sample Men Women Difference 
Item Condition 
present 
     n     (%) 
Condition 
present 
         n       (%) 
Condition 
present 
   n      (%) % Mean (SE) ‡ Mean (SE) ‡ Mean (SE) ‡ 
 
1 Hypertension 297 (50.7) 130 (52.3) 167 (49.4) -2.9 1.57 0.06 1.61 (0.09) 1.54 (0.08) -0.07 
2 Myocardial infarction 24 (4.1) 17 (6.1) 7 (2.5) -3.6^ 2.84 0.28 2.68 (0.35) 3.14 - 0.46 
3 Heart failure 59 (9.7) 31 (10.4) 28 (9.2) -1.2 2.42 0.20 2.04 (0.34) 2.77 (0.20) 0.73 
4 Angina 27 (4.2) 12 (4.2) 15 (4.2) 0 2.06 0.22 1.84 (0.05) 2.23 (0.43) 0.39 
5 Circulation problems/ 
intermittent claudication 
137 (24.1) 37 (13.9) 100 (32.3) 18.4* 2.18 0.10 1.77 (0.14) 2.32 (0.13) 0.55** 
6 Osteoarthritis 278 (47.1) 68 (25.1) 210 (64.8) 39.4* 2.77 0.08 2.45 (0.16) 2.87 (0.09) 0.42* 
7 Rheumatoid arthritis 135 (22.3) 31 (9.7) 104 (32.5) 22.8* 2.91 0.13 2.51 (0.25) 3.01 (0.16) 0.52** 
8 Asthma 33 (5.2) 15 (5.2) 18 (5.3) 0.1 2.60 0.17 2.99 - 2.30 (0.19) 0.31 
9 COPD/emphysema 49  (8.4) 33 (12.1) 16 (5.4) -6.7^ 2.57 0.23 2.56 (0.11) 2.58 - 0.02 
10 Diabetes 90 (15.6) 47 (17.6) 43 (13.9) -3.7 1.94 0.12 1.64 (0.11) 2.23 (0.15) 0.59** 
11 Gastric/duodenal ulcer 68 (11.3) 36 (13.0) 32 (10.0) -3.0 1.76 0.16 1.56 (0.26) 1.98 (0.30) 0.42 
COPD, Chronic Obstructive Pulmonary Disease; SE, Standard Error 
† Unweighted counts and weighted percentages 
 ‡ missing SE values are due to very low prevalences 
*p<0.001; **p<0.01; ^p<0.05 
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Table 4.7. Prevalences and mean disease burden scores per condition per sex in de studied sample (n=625): men (n=280) vs. women (n=345) 
continued 
 
 Prevalence†  Disease burden score  
 Total sample Men Women Difference Total sample Men Women Difference 
Item Condition 
present 
n (%) 
Condition 
present 
n (%) 
Condition 
present 
n (%) 
 Mean  (SE) ‡ Mean  (SE) ‡ Mean  (SE) ‡  
12 Kidney disease 55 (9.4) 23 (8.8) 32 (10.0) 1.2 1.76 0.18 1.81 (1.34) 1.73 (0.23) -0.08 
13 Depression 109 (18.8) 20 (7.0) 89 (28.3) 21.3* 2.48 0.15 1.97 (0.55) 2.58 (0.15) 0.61 
14 Anxiety 77 (13.1) 15 (5.6) 62 (19.2) 13.6* 2.60 0.16 2.44 (0.36) 2.63 (0.18) 0.19 
15 Cerebral embolism/stroke 23 (4.4) 9 (3.6) 14 (5.0) 1.4 2.04 0.47 1.61 (0.44) 2.29 (0.98) 0.68 
16 Cancer 67 (11.1) 42 (15.7) 25 (7.5) -8.2** 2.03 0.20 1.88 (0.28) 2.29 (0.29) 0.41 
17 Osteoporosis 101 (17.1) 6 (1.9) 95 (9.3) 7.4* 2.50 0.16 2.69 - 2.49 (0.16) -0.20 
18 Memory disorders 15 (2.7) 6 (2.3) 9 (2.9) 0.6 2.53 - 2.77 - 2.37 - -0.40 
19 Parkinson's disease 8 (1.4) 3 (1.0) 5 (2.0) 1.0 2.96 0.55 2.85 - 3.00 (0.60) 0.15 
20 Chronic back pain 128 (22.3) 31 (11.6) 97 (30.9) 19.3* 2.92 0.15 2.55 (0.25) 3.03 (0.16) 0.48 
21 Urinary tract problems 
(prostate, bladder) 
113 (19.3) 78 (28.8) 35 (11.7) -17.1* 2.21 0.13 1.95 (0.18) 2.73 (0.20)  0.78** 
SE, Standard Error 
† Unweighted counts and weighted percentages 
 ‡ missing SE values are due to very low prevalences 
*p<0.001; **p<0.01; ^p<0.05 
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4.3.2. KNOWN-GROUPS VALIDITY BY AGE GROUPS 
 
Table 4.8 shows the prevalences and mean disease burden scores per condition, by age 
group (<75 years vs. ≥75 years). Hypertension was, as in the total sample, the most 
frequent condition in both age groups (n=155, 47.2% in the <75 years age group and 
n=142, 55.0% in the ≥75 years age group). Also, in both groups hypertension showed the 
lowest mean disease burden score, with a mean value of 1.6 (SE=0.1). In the <75 years age 
group, myocardial infarction (3.0, SE=0.2) showed the highest mean disease burden score. 
In the ≥75 years age group, the highest score was found for rheumatoid arthritis (3.0, 
SE=0.2).   
 
Persons aged 75 years and older had a mean number of chronic conditions of 3.49, vs. 3.01 
in persons aged <75 years (difference: 0.48, p=0.002). When studying these differences for 
single diseases, three conditions were significantly more frequent in the older group: 
rheumatoid arthritis, kidney disease and urinary tract problems. For one of the conditions 
(osteoarthritis) a significantly higher disease burden score was found among persons aged 
75 years and older than among younger participants.  
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Table 4.8. Prevalences and mean disease burden scores per condition and age group in the 
studied sample (n=625): <75 years (n=350) vs. ≥75 years (n=275) 
 Prevalence†  Disease burden score  
 <75 years ≥75 years Difference <75 years ≥75 years Difference 
          Item 
Condition 
present 
   n      (%) 
Condition 
present 
      n      (%) % Mean (SE) ‡ Mean (SE) ‡  
1 Hypertension 155 (47.2) 142 (55.0) 7.8 1.57 (0.09) 1.57 (0.09) 0 
2 Myocardial 
infarction 
10 (3.0) 14 (5.5) 2.5 2.98 (0.22) 2.74 (0.61) -0.24 
3 Heart failure 26 (7.8) 33 (12.1) 4.3 2.52 (0.27) 2.34 (0.30) -0.18 
4 Angina 14 (4.1) 13 (4.3) 0.2 2.22 (0.91) 1.86 - -0.36 
5 Circulation 
problems 
64 (20.9) 73 (28.0) 7.1 2.15 (0.16) 2.21 (0.17) 0.06 
6 Osteoarthritis 145 (44.5) 133 (50.2) 5.7 2.61 (0.11) 2.94 (0.13) 0.33* 
7 Rheumatoid 
arthritis 
60 (17.6) 75 (28.2) 10.6** 2.78 (0.16) 3.00 (0.20) 0.22 
8 Asthma 18 (5.3) 15 (5.2) -0.1 2.30 - 2.99 (0.17) 0.69 
9 COPD/emphysema 24 (8.0) 25 (8.9) 0.9 2.36 (0.50) 2.80 (0.24) 0.44 
10 Diabetes 46 (14.7) 44 (16.6) 1.9 2.17 (0.20) 1.67 (0.18) -0.50 
11 Gastric/duodenal 
ulcer 
43 (13.0) 25 (9.3) -3.7 1.76 (0.28) 1.78 (0.28) 0.02 
12 Kidney disease 23 (7.0) 32 (12.4) 5.4** 1.68 (0.31) 1.83 (0.27) 0.15 
13 Depression 61 (19.5) 48 (18.0) -1.5 2.47 (0.24) 2.49 (0.18) 0.02 
14 Anxiety 47 (15.4) 30 (10.4) -5.0 2.53 (0.17) 2.72 (0.24) 0.19 
15 Cerebral 
embolism/stroke 
11 (3.6) 12 (5.3) 1.7 2.57 (0.71) 1.58 (0.31) -0.99 
16 Cancer 34 (10.7) 33 (11.7) 1.0 1.99 (0.40) 2.07 (0.32) 0.08 
17 Osteoporosis 86 (17.4) 45 (16.7) -0.7 2.41 (0.15) 2.61 (0.28) 0.20 
18 Memory disorders 8 (2.6) 7 (2.7) 0.1 2.84 - 2.16 - -0.68 
19 Parkinson's 
disease 
4 (1.1) 4 (1.8) 0.7 2.58 - 3.25 (0.43) 0.67 
20 Chronic back pain 70 (22.1) 58 (22.5) 0.4 2.86 (0.18) 2.98 (0.24) 0.12 
21 Urinary tract 
problems  
45 (15.3) 68 (24.3) 9.0* 2.13 (0.28) 2.28 (0.22) 0.15 
COPD, Chronic Obstructive Pulmonary Disease; SE, Standard Error 
† Unweighted counts and weighted percentages 
 ‡ missing SE values are due to very low prevalences 
*p<0.01; **p<0.05 
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4.3.3. CONVERGENT VALIDITY: ASSOCIATION WITH PATIENT-CENTERED 
MEASURES AND HEALTHCARE UTILIZATION  
 
All independent variables were significantly associated with the DBMA in the bivariate 
models (Table 4.9). The final multivariate regression model included 503 individuals, due 
to missing values in the independent variables. Female sex , primary/outpatient care and 
hospital care showed a significant and positive association with the DBMA. Perceived 
health, functional status, QoL, and affect balance and were negatively associated with 
disease burden. No significant associations were found for age. The model explained 42% 
of the variance. 
 
Age was significantly associated with the DBMA in the bivariate analysis and no longer in 
the multivariate analysis. Therefore, a confounding analysis was performed (Table 4.10):  
perceived health and physical functioning were the variables that influenced the 
association with the DBMA in a negative way and showed significant associations with age.  
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Table 4.9. Association of patient-centered variables and healthcare utilization with disease 
burden: raw and adjusted linear models 
 
 Bivariate analysis  Multivariate model 
Variable Coefficient p-value Coefficient p-value 
Intercept   3.126 <0.001 
Female sex 0.598 <0.001 0.192 0.024 
Age 0.017 0.019 0.009 0.145 
Very good/good perceived health -0.928 <0.001 -0.424 <0.001 
Physical functioning (no disability) -0.933 <0.001 -0.532 <0.001 
QoL (PWI) -0.040 <0.001 -0.024 <0.001 
Affect balance (SPANE) -0.045 <0.001 -0.013 0.022 
Primary/outpatient care in the past month 0.670 <0.001 0.358 <0.001 
Hospital care in the past year 0.401 <0.001 0.186 0.040 
R² for multivariate model=0.42, n=503 
PWI, Personal Wellbeing Index; QoL, Quality of Life; SPANE, Scale of Positive and Negative 
Experience 
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Table 4.10. Regression coefficients between age and disease burden adjusted for each of 
the potential confounding variables separately and the relation between age and these 
variables 
Regression coefficient   
Raw 0.017 Linear regression with age 
Adjusted for:   coefficient p-value 
Sex 0.017 0.45 0.415 
Perceived health 0.012 -1.57 0.006 
Physical functioning 0.006 -3.44 <0.001 
Quality of life (PWI) 0.022 -0.04 0.170 
Affect balance (SPANE) 0.018 0.02 0.625 
Use of outpatient care 0.015 0.59 0.372 
Use of hospital care 0.018 -0.61 0.300 
PWI, Personal Wellbeing Index; QoL, Quality of Life; SPANE, Scale of Positive and Negative 
Experience 
 
Variables in bold are those with a change-in-estimate of ≥20% and a significant association with 
age 
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4.3.4. PREDICTIVE VALIDITY: ASSOCIATION WITH MORTALITY 
 
After four years, 35 of the 625 participants had died (5.5%). The Cox regression model 
showed a higher adjusted risk of death for persons with a higher score on the DBMA scale 
than for persons with lower scores: HR=1.073, 95% CI=1.002-1.148, p=0.044 (Table 4.11). 
When not correcting for complex samples, the HR remained practically the same (HR= 
1.076, CI=1.027-1.128), but the p-value decreased to 0.002. The area under the ROC curve 
for the logistic regression model was 0.803 (Figure 4.4), with a 95% CI of 0.727-0.879. 
 
Figure 4.5 shows the Kaplan-Meier curves for different DBMA categories. Persons with 
DBMA scores ≤ 2 had a higher survival rate than persons with higher DBMA scores. 
Although less pronounced, the remaining two categories (3-10, ≥11 DBMA scores) 
followed the same trend, with the lowest survival rate for persons in the highest DBMA-
score category. 
 
 
 
Table 4.11. Disease burden as a predictor of mortality: Cox regression  
 
 Corrected for complex samples (n=503) Raw data (n=625) 
Variable HR SE p-value 95% CI HR SE p-value 95% CI 
DBMA 1.073 0.037 0.044 1.002-1.148 1.076 0.026 0.002 1.027-1.128 
Age 1.085 0.035 0.013 1.017-1.157 1.108 0.029 <0.001 1.051-1.167 
Sex 0.108 0.082 0.004 0.024-0.483 0.099 0.048 <0.001 0.038-0.257 
CI, Confidence Interval; DBMA, Disease Burden Morbidity Assessment; HR, Hazard Ratio; SE, 
Standard Error 
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Figure 4.4. Receiver Operating Characteristic (ROC) curve of the logistic regression model 
with mortality as a dependent variable 
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Figure 4.5. Kaplan Meier probability of survival per DBMA category 
 
DBMA, Disease Burden Morbidity Assessment 
Applied DBMA cut-off points: low, 0-2; medium, 3-10; high, ≥11. 
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4.4. RESULTS OF STUDY 3: RASCH ANALYSIS 
 
4.4.1. RASCH ANALYSIS 
 
The initial analysis, with the whole study sample (n=1400), displayed poor fit to the Rasch 
model (Table 4.12). After selecting a subsample of 300, the fit indices improved, but still 
did not meet the fit criteria. Category probability curves showed disordered thresholds, so 
items were rescored to two (two items), three (13 items), four (five items) or four 
categories (one item) (Table 4.13). After this, the DBMA showed an acceptable fit to the 
Rasch model (Table 4.12). Individual item and person fit residuals were within the -2.5 to 
+2.5 range, with non-significant chi-squares (Table 4.13). However, PSI remained low, 
0.272. When repeating this estimation in RUMM2020 the PSI improved to 0.637.  
 
In the PCA of the residuals, 0.72% of tests were outside the previously set range, 
indicating unidimensionality. All items were locally independent, with a residual 
correlation index ranging 0.000-0.188. No DIF was found for age or educational level. Four 
items showed DIF by sex of small magnitude (< 0.5 logits): item 1 (hypertension), 14 
(anxiety), 17 (osteoporosis) and 21 (urinary tract problems). In the top-down purification 
approach this DIF was no longer present. The person-item threshold distribution (Figure 
4.6) showed a floor effect and no persons represented the scale’s higher levels of disease 
burden.  
 
DBMA scores of the total sample were converted into a linear measure from 0 to 47 (Table 
4.14). When comparing the subsample of 300 and the rest of the sample, the differences 
between the estimations were not significant (difference=0.259 logits, t-test= 1.226, p-
value=0.226), and there was no DIF by sample. 
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Table 4.12. Global fit to the Rasch model of the DBMA using the total sample (n=1400), 
after selecting a subsample (n=300) and after rescoring the response scale 
  
Standard 
Total 
sample Subsample 
After 
rescoring 
Item fit residual Mean 0 -2.90 -1.12 -0.68 
 SD 1 1.83 0.77 0.71 
Person fit residual Mean 0 -0.48 -0.42 -0.28 
 SD 1 0.59 0.58 0.55 
Item-trait 
interaction  
² Low 316.33 165.14 154.43 
 Prob. NS <0.001 0.89 0.32 
PSI  >0.70 0.07 0.14 0.27 
Unidimensionality Significant 
t-tests (%) 
< 5 0.72 2.00 2.00 
NS, non-significant; PSI, Person Separation Index; Prob, Probability; SD, Standard Deviation 
 
Note: Item fit residual refers to the difference between the data observed and the expected values 
at item level.  
Person fit refers to the difference between the data observed and the expected values at person 
level. 
Item-trait interaction is a chi-square value and probability resulting from the comparison between 
the expected and the mean observed score for groups of people with similar ability estimates. 
Person separation index is a reliability measure. 
Unidimensionality refers to the existence of one measurement construct (dimension) underlying 
the set of items. 
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Table 4.13. Threshold ordering of polytomous items and individual item fit to the Rasch 
model after rescoring (n=300) 
 Original categories  Individual item fit to the Rasch model 
 
0 1 2 3 4 5       
Item Rescored categories  Location SE Residual ² Prob. 
Osteoarthritis 0 1 1 1 2 3  -1.914 0.093 -2.020 14.737 0.040 
Rheumatoid arthritis 0 1 1 1 2 3  -1.514 0.108 -1.749 5.988 0.541 
Chronic back pain 0 1 1 1 1 2  -1.392 0.130 -0.707 10.910 0.143 
Depression 0 1 1 1 1 2  -1.161 0.140 -0.996 7.631 0.366 
Circulation problems/ 
intermittent claudication 0 1 1 1 2 3 
 
-0.965 0.134 -1.698 5.237 0.631 
Hypertension 0 1 2 2 3 4  -0.934 0.088 -0.515 16.122 0.024 
Anxiety 0 1 1 1 1 2  -0.858 0.160 -1.474 7.290 0.399 
Osteoporosis 0 1 1 1 1 2  -0.644 0.162 -1.271 3.796 0.803 
Cancer 0 1 1 1 2 3  -0.515 0.160 0.068 8.254 0.311 
Diabetes 0 1 1 1 1 2  -0.371 0.174 -0.637 6.877 0.442 
Heart failure 0 1 1 1 1 2  -0.331 0.196 -0.055 8.192 0.316 
Urinary tract problems (prostate, 
bladder) 0 1 1 1 2 3 
 
-0.219 0.147 -0.436 6.327 0.502 
COPD/emphysema 0 1 1 1 1 2  -0.137 0.222 -0.162 5.471 0.603 
Cerebral embolism/stroke 0 1 1 1 1 1  0.296 0.353 0.171 10.195 0.178 
Memory disorders 0 1 1 1 1 1  0.310 0.355 -0.424 5.818 0.561 
Gastric/duodenal ulcer 0 1 1 1 1 2  1.081 0.199 0.849 9.992 0.189 
Kidney disease 0 1 1 1 1 2  1.190 0.218 -0.444 7.298 0.399 
Asthma 0 1 1 1 1 2  1.578 0.274 -1.258 5.272 0.627 
Myocardial infarction 0 1 1 1 1 2  1.685 0.296 -0.340 2.781 0.904 
Angina 0 1 1 1 1 2  2.039 0.473 -0.312 4.173 0.760 
Parkinson's disease 0 1 1 2 2 2  2.776 0.924 -0.912 2.071 0.956 
COPD, Chronic Obstructive Pulmonary Disease; SE, Standard Error; Prob., Probability 
Items are ordered by increasing difficulty (mean location of thresholds)
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Table 4.14. Initial score to linear measure conversion table (final Rasch model), n=1400 
Initial score 
Linear 
measure 
(logit scale) 
Linear 
measure 
 (0-47) Initial score 
Linear 
measure 
 (logit scale) 
Linear 
measure 
(0-47) 
0 -4.178 0.000 24 -0.164 23.202 
1 -3.406 4.462 25 -0.085 23.659 
2 -2.891 7.439 26 -0.005 24.121 
3 -2.547 9.428 27 0.076 24.590 
4 -2.287 10.931 28 0.158 25.064 
5 -2.075 12.156 29 0.241 25.543 
6 -1.897 13.185 30 0.326 26.035 
7 -1.741 14.087 31 0.413 26.538 
8 -1.602 14.890 32 0.503 27.058 
9 -1.477 15.613 33 0.596 27.595 
10 -1.362 16.277 34 0.693 28.156 
11 -1.255 16.896 35 0.794 28.740 
12 -1.155 17.474 36 0.901 29.358 
13 -1.060 18.023 37 1.014 30.012 
14 -0.969 18.549 38 1.136 30.717 
15 -0.882 19.052 39 1.268 31.480 
16 -0.798 19.538 40 1.415 32.329 
17 -0.715 20.017 41 1.578 33.272 
18 -0.635 20.480 42 1.766 34.358 
19 -0.555 20.942 43 1.988 35.642 
20 -0.477 21.393 44 2.261 37.220 
21 -0.398 21.850 45 2.620 39.295 
22 -0.320 22.301 46 3.156 42.393 
23 -0.242 22.751 47 3.953 47.000 
 
Note: This table is not applicable when there are missing data. 
To use this table, first score items according to Table 4.13. The sum of items scores is the 
“initial score”, which can be converted to a linear measure in logits (second column) or a 
0-47 scale (third column). 
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Figure 4.6.Person-item threshold distribution map: final Rasch analysis of the DBMA 
 
Item01. Hypertension; Item02. Myocardial infarction; Item03. Heart failure; Item04. Angina; Item05. 
Circulation problems/ intermittent claudication; Item06. Osteoarthritis; Item07. Rheumatoid arthritis; Item08. 
Asthma; Item09. COPD/emphysema; Item10. Gastric/duodenal ulcer; Item11. Gastric/duodenal ulcer; Item12. 
Kidney disease; Item13. Depression; Item14. Anxiety; Item15. Cerebral embolism/stroke; Item16. Cancer; 
Item17. Osteoporosis; Item18. Memory disorders; Item19. Parkinson's disease; Item20. Chronic back pain; 
Item21. Urinary tract problems (prostate, bladder) 
 
Note: Persons are represented on the left side, each 'x' representing 3 persons. On the 
right side of the graphic, item thresholds are represented, with the corresponding 
threshold for each item after the dot. 
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4.4.2. CLASSIC PSYCHOMETRIC ANALYSIS OF THE LINEAR MEASURE 
 
The distribution of the linear measure is shown in Figure 4.7. Mean score was 7.36 
(SD=5.01), median score 7.44, with a mean-median difference of 0.17%. Floor effect for 
the total scale was 18.11%, with no ceiling effect, and skewness was 0.046. The linear 
measure presented a correlation of -0.48 with physical functioning, -0.47 with perceived 
health, 0.32 with depression (CES-D) and -0.24 with PWI (p<0.001). Women scored 
significantly higher than men, with mean scores of 8.14 (SD=5.15) and 6.40 (SD=4.65), 
respectively (p<0.001), and scores increased with age: mean score among persons <65 
years was 5.93 (SD=4.76) vs. a mean score of 8.77 (SD=4.84) in persons aged ≥65 years 
(p<0.001).  
 
The results of the relative precision analysis are shown in Table 4.15. The ability to 
discriminate between age groups increased by 9% when using the linear measure vs. the 
raw score (95%CI: 1.03-1.17), but precision decreased 4% for age groups, although this 
difference was not statistically significant (95% CI: 0.86-1.05).  
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Figure 4.7. Distribution of the linear measure (n=1397) 
 
 
 
Table 4.15. Relative precision of the linear measure in comparison to the raw summative 
DBMA score (n=1277)    
 
Scoring 
method 
Patient 
groups 
Mean (SE) Mean difference 
(SE) 
Z statistic RP 95% CI 
Raw score <65 years 3.81 (0.20) 3.02 (0.35) -9.89 1.00  
≥65 years 6.83 (0.28)  
Linear 
measure 
<65 years 5.95 (0.19) 2.98 (0.26) -10.77 1.09 1.03-1.17 
≥65 years 8.92 (0.19)  
Raw score Men 3.88 (0.19) 2.59 (0.35) -6.61 1.00  
Women 6.47 (0.28)  
Linear 
measure 
Men 6.43 (0.19) 1.78 (0.27) -6.33 0.96 0.86-1.05 
Women 8.21 (0.19)  
CI, Confidence Interval; SE, Standard Error; RP, Relative Precision 
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5. DISCUSSION 
 
This work describes validation of the DBMA, a comorbidity assessment instrument that 
incorporates a dimension not usual in other comorbidity measures: the disease burden 
caused by the present chronic conditions. Co- or multimorbidity requires a patient-
centered healthcare approach, with a more holistic view that goes beyond treating single 
diseases (8). Since chronic conditions usually cannot be cured, the goal of caring for 
persons with multimorbidity should be mostly centered in maximizing QoL (41). 
Therefore, interventions to improve care for this population often assess subjective 
outcomes as QoL and emotional wellbeing rather than objective outcomes. These 
subjective outcomes reflect what is most meaningful to the patients themselves. However, 
patient reported outcomes may be influenced by other factors than multimorbidity itself. 
The DBMA provides a subjective measure that is directly related to multimorbidity. By 
asking patients about the impact of chronic conditions on their daily activities, without 
specifying which activities or the kind of impact, the DBMA measures not only physical but 
also psychological limitations on a broad spectrum of everyday activities. This makes the 
DBMA an extremely useful subjective measure of multimorbidity, or better said, the 
disease burden caused by multimorbidity.  
 
This thesis presents the results of a validation of the DBMA according to the CTT 
(objective 1: feasibility, acceptability, scaling assumptions, reliability, construct validity 
and exploratory factor analysis), including known-groups, convergent and predictive 
validity (objective 2), and Rasch analysis (objective 3: test of fit to the Rasch model, 
reliability, unidimensionality, response dependency, category structure, DIF, scale 
targeting and CTT analysis of the linear measure). 
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5.1. STUDY 1: VALIDATION OF THE DBMA ACCORDING TO THE CTT 
 
In order to perform a validation according to the CTT, the following psychometric 
properties were studied: feasibility, acceptability, scaling assumptions, reliability and 
construct validity.  Dimensionality was assessed through an exploratory factor analysis.  
 
Feasibility was assessed by determining the percentage of missing values per item and the 
percentage of computable scores for the total scale. The percentages of missing values per 
item were all below the 10% criterion. However, the percentage of computable scores was 
just below the criterion of 90%. The DBMA in this study was part of the CAPI 
questionnaire which consisted of 218 questions. The fact that the DBMA was included in 
such a large questionnaire might have influenced the willingness and capability to answer 
the questions of the DBMA.  
 
Acceptability was explored by comparing possible and observed scores, mean-to-median 
difference for the total scale as well as floor and ceiling effects and skewness. The 
observed scores covered the complete response ranges for the 21 items, except for 
Parkinson´s disease, which had a response rate of 0-4 but also a very low prevalence. For 
the total scale a response range of 0-41 was observed, which was way below the 
hypothetic maximum score of the DBMA of 105. However, the DBMA was not designed to 
cover the complete total score range, since this would mean the presence of all 21 chronic 
conditions in the same person, with a maximum impact on daily life. Therefore, the 
observed range coincided with our expectations. Mean to median difference was within 
the set criterion.  
 
One of the most remarkable findings in this analysis has been the floor effect (and, as a 
consequence, the high value for skewness). The high floor effects represent cases in which 
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participants reported not having certain conditions. This implies that the floor effect can 
actually be regarded as an indicator of how 'healthy' the studied population is. The sample 
used in this study consisted of community-dwelling adults, with quite a high health status. 
Institutionalized persons were not included, which made that the ELES-PS sample was 
healthier than the general population. Rodríguez Laso et al. (105) conducted a study about 
selection bias in the ELES-PS.  They found that the persons that refused to participate in 
the CAPI interview, the questionnaire that contained the DBMA, were of higher age and 
reported lower perceived health than the respondents who did answer this questionnaire 
(105). Also, only persons with household telephone lines were selected. The proportion of 
persons aged 50 years and older in Spain with telephone lines is estimated to be at least 
92% (105), but it is possible that people that do not have a telephone line have lower 
incomes, which is known to be related to lower health status (106). Nevertheless, even 
when using the DBMA in a sample with high prevalence of multimorbidity, high floor 
effects per item would still be found, because there would still be a high number of non-
present conditions in every participant. 
 
When studying disease burden scores for only the present conditions, the floor effects 
persisted, though less pronounced. This means that the participants in the used sample 
often responded that they did not experienced any limitation because of their chronic 
conditions. Hypertension, kidney disease and gastric/duodenal ulcer all showed floor 
effects above 60%. In the case of kidney disease, this is a little surprising. Chronic kidney 
diseases are known to be associated with poor physical function and to have a negative 
effect on activities of daily living (107–109). This raises the question whether the 
participants really did not experience disease burden from their kidney diseases or if they 
might have wrongly qualified any other conditions as kidney diseases. Including examples 
of the listed conditions, as was done by Bayliss et al (41), could help to prevent confusion 
about the listed conditions. Another option would be to ask the participants to specify 
77 
 
which particular conditions they have, however, this would make the questionnaire more 
laborious, both for the respondent and for the interpretation of the questionnaires.   
 
Two conditions showed a ceiling effect when only including present conditions: 
COPD/emphysema and memory disorders. This means that these were the two conditions 
with the highest proportion of a maximum disease burden. However, also these two 
conditions showed important floor effects. It seems like for these two conditions, the 
limitations followed an ‘all nor nothing’ pattern: either they do not limit daily activities, or 
they do a lot. In any case, the high ceiling effects coincide with the literature, as both 
conditions are known to cause important limitations of daily living activities. In case of 
COPD these limitations are mainly physical (110–112); for dementia it is the cognitive 
impairment that might limit patients in their daily life (113,114).  
 
One more comment should be made about the floor- and ceiling effects. As can be seen in 
Table 3.1, and as done by Bayliss et al. (45), the middle response categories of the 
response scale were not labelled. This could have prevented participants from choosing 
the middle options. Further research might include these labels in order to assess whether 
this would make participants more likely to choose the middle response options.  
 
Scaling assumptions were determined through the ITCC for each item. There were only six 
conditions that met the criterion: osteoarthritis, intermittent claudication, rheumatoid 
arthritis, chronic back pain, depression and anxiety. These conditions have in common is 
that they are all among the 10 most prevalent conditions in our sample. Apparently, the 
ITCC improves when the prevalence increases. This implies that also the low ITCC for the 
remaining conditions could be explained by the fact that the ELES-PS  sample was 
relatively healthy, and would probably improve in more comorbid populations. We did not 
expect to find high ITCC because the scores for individual conditions are not necessarily 
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related to the total scores: experiencing high disease burden from one disease does not 
mean that the other 20 conditions should be present as well. However, having comorbid 
conditions does increase the disease burden experienced from a specific disease (115,116), 
which might have caused the ITCC to be higher in the more prevalent conditions. 
 
Reliability was assessed through Cronbach’s alpha, which did meet the criterion for group 
comparisons. Cronbach´s alpha is a measure that indicates to what extent the items 
measure the same construct. In this case, the construct was disease burden, and 
Cronbach´s alpha confirmed that this was the same for all items. Reliability will be further 
addressed in the discussion section about Rasch analysis.  
 
The item homogeneity index, the mean of inter-item correlations, was extremely low. As 
explained above, the items of the DBMA were not designed to be associated to each other 
nor to the total score, and therefore, it was not a surprise to find a low homogeneity index.  
 
For convergent validity, we expected self-reported disease burden to be negatively 
associated with perceived health, physical functioning and QoL and to find a positive 
association with depression (10,80,81). Furthermore, these correlations were compared 
with those of the simple disease count of the 21 conditions included in the DBMA. ELES-PS 
data confirmed that the DBMA is more strongly associated with depression, perceived 
health and physical functioning than the number of conditions, although these differences 
were less pronounced than in the study published by Bayliss and colleagues (41).  This 
outcome is of interest because, although the DBMA is a relatively short questionnaire, it is 
still more laborious than a simple disease count. The association between a simple count 
of chronic conditions as a measure of multimorbidity and QoL has widely been studied 
(117,118). However, measures taking into account disease severity seem to be better 
predictors of QoL (119), as was confirmed in this study. The relationship between the 
79 
 
DBMA and the PWI, a general QoL measure, had not been studied yet and this study has 
found a moderate correlation. Some of the dimensions of this scale are not directly related 
to health, such as personal safety and future security (73), and the correlation with a scale 
measuring health related QoL could possibly be stronger.  
 
Known-groups validity was examined comparing disease burden by sex and age groups. 
Our hypothesis to find higher scores in women and older people was confirmed. The 
difference between men and women was especially pronounced. This can be explained by 
the fact that not only multimorbidity is more frequent among women, but women also 
experience more functional limitations for every additional chronic condition (120). This 
will be further addressed in the discussion section about Study 2. 
 
The factor analysis identified known disease groups (121). Intermittent claudication is a 
motor symptom and therefore it was probably more related to musculoskeletal disorders 
than to cardiovascular diseases.  Dimensionality was also assessed in Rasch analysis, so 
the findings of this factor analysis will be further discussed below.  
 
In summary, Study 1 found satisfactory feasibility and acceptability for the DBMA, except 
for large floor effects, which could be explained by the design of the DBMA as well as by 
the high health status of the used sample. Items were not highly related to each other nor 
to the total score (low ITCC and item homogeneity index) but, according to Cronbach´s 
alpha, DBMA items do measure the same construct: disease burden. The construct validity 
analysis found the DBMA to be related to other patient-centered outcomes. Construct 
validity was further studied in Study 2.   
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5.2. STUDY 2: KNOWN-GROUPS, CONVERGENT AND PREDICTIVE 
VALIDITY  
 
In this study, known-groups validity by sex and age groups was assessed more thoroughly. 
In addition convergent validity was further assessed by analyzing the association between 
the DBMA, other patient-centered outcomes and healthcare utilization. Finally, predictive 
validity was studied through the association with mortality. 
 
5.2.1. KNOWN-GROUPS VALIDITY 
 
In the known-groups validity analysis of Study 1, women and persons aged 75 years and 
older had significantly higher disease burden scores. In Study 2, this was assessed per 
condition. The mean number of present conditions and disease prevalences were also 
compared for these groups, in order to find out whether the results found in Study 1 were 
due to differences in disease prevalence, or due to differences in disease burden per 
present condition.  
 
As described in the discussion of Study 1, we expected disease burden per condition to be 
higher in women, since women are known to experience more functional limitations per 
present condition (120). Indeed, for five conditions, women reported a significantly higher 
mean disease burden score per present condition. Most of the differences in disease 
burden we not significant, which can be ascribed to the low prevalences of the conditions, 
resulting in very few disease burden scores per condition. Significant differences were 
found for the most prevalent conditions. Women had a significantly higher mean number 
of present conditions than men and seven of the conditions were more frequent in women, 
versus five conditions that were more prevalent in men. From these data, it can be 
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concluded that the women in this sample showed higher disease burden scores, caused by 
both higher disease prevalences and higher disease burden per condition.  
 
The question remains why women experience higher disease burden per present 
condition than men. This question cannot be easily answered. Do women have more 
serious diseases or do they ‘complain’ more? A possible explanation, as described by Hunt 
et.al.(122), is that women have more traditional “role obligations” than men, since their 
duties include more elements of caretaking. This article was published in 1984 and more 
than 30 years have gone by since then, but these roles probably remain largely unchanged 
among older Spanish adults. 
 
The increase in disease burden with age was less clear. Only one condition, osteoarthritis, 
showed a significantly higher disease burden when present in the ≥75 years of age group. 
The mean number of conditions per person was higher in older participants and three 
conditions were significantly more frequent among the highest age group. These results 
suggest that for age, the differences in disease burden scores were more due to differences 
in disease prevalence rather than differences in the disease burden caused by every 
present condition. This conclusion coincides with a study performed by Henchoz et al 
(123). They found that, although the number of conditions increased rapidly with age in 
octogenarians, their perceived health decreased in a much less steep way. This was 
explained by the fact that older people compare their health to that of persons of the same 
age. Since chronic conditions are frequent among older people, participants often 
concluded that their own health status was not that bad or it was even better than their 
peers’ health. The same mechanism might be applied to disease burden. Older persons 
might be more limited by their conditions, but since limitations are common in their age 
group, they do not experience them as serious as younger people.  
 
82 
 
5.2.2. CONVERGENT VALIDITY 
 
In the multivariate analysis, significant associations between the DBMA and perceived 
health, functional status, QoL, and affect balance were found. These results confirm the 
associations found in previous studies between the DBMA and patient-centered outcomes, 
(41,45,46) and are congruent with findings from Study 1. The relation between the DBMA 
and the SPANE as a measure of affect balance had not been studied before. A negative 
association between affect balance and self-reported disease burden was found. This was 
expected, since studies have shown that the SPANE is negatively associated with 
depression (87), and depression positively associated with the DBMA (41).  
 
The multivariate regression showed no significant relation between the DBMA and age, 
but female sex was positively associated with self-reported disease burden, indicating that 
women had higher scores on this scale, as was also concluded in Study 1 and the known-
groups validity assessment in the current study. When assessing confounding factors, 
perceived health and physical functioning had a negative impact on the association 
between age and the DBMA. These findings are consistent with the literature since older 
people have lower perceived health(124) and poorer physical functioning(125), and these 
variables themselves are associated with the DBMA. 
 
The use of healthcare resources was added in this analysis as a system-centered outcome. 
The term system-centered outcome can be described as an outcome that can be expressed 
in healthcare costs, whereas patient-centered outcomes are variables that are of high 
importance for individual patients, such as QoL (126).The measures of healthcare use 
were self-reported, which implies that some level of subjectivity should be taken into 
account. In a recent Dutch study, community-dwelling older persons slightly 
overestimated healthcare utilization, and this was more frequent among people with 
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multimorbidity and among those who reported having a worse heath-status than a year 
before (127). However, their overall conclusion was that self-report of healthcare 
utilization in older community-dwelling persons was adequate and efficient.  
 
A significant positive association between the DBMA and primary/outpatient care and 
hospital care was found. This second association was weaker and less significant. This can 
be due to two reasons. First, primary/outpatient care was twice as frequent in the used 
sample as hospital care. Second, the hospital care variable referred to the past year, 
whereas primary/outpatient care referred to month prior to the interview, which could 
make it more related to the disease burden experienced at that moment.  
 
Bayliss et al. previously studied the relationship between the DBMA and utilization 
outcomes (46). They reported significant associations with outpatient utilization and 
inpatient admissions; the relation with emergency department admissions was not 
significant. They did the same analysis for the Charlson Comorbidity Index (CCI), finding 
significant associations with the three utilization outcomes with stronger associations 
than the DBMA. Their results found for the DBMA are similar to the results in the current 
study; it seems that there is a relationship between the DBMA as a patient-centered 
multimorbidity scale and the system-centered outcome of healthcare utilization. However, 
healthcare utilization was more related to the CCI and it might be more appropriate to use 
a more system-centered multimorbidity scale such as the CCI when predicting the use of 
healthcare resources (26,46).  
 
Descriptive statistics were presented for the whole sample used in Study 2 as well as for 
the sample used in the multivariate regression model. Due to missing values in the 
variables in the multivariate regression model, this sample was reduced to 503. However, 
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the reduced sample resulted quite similar to the total sample, so this reduction should not 
have influenced the conclusions drawn in this analysis.  
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5.2.3. PREDICTIVE VALIDITY 
 
For predictive validity, the longitudinal association of the DBMA with four-year mortality 
was assessed. The DBMA was designed and validated to be associated with patient-
centered outcomes, unlike other multimorbidity assessment scales such as the CCI and 
Elixhauser´s comorbidity measure where mortality was one of the main outcomes of 
interest (24,29). To the best of our knowledge, the relationship between the DBMA and 
mortality had not been studied yet. A positive association between the DBMA and 
mortality after four years follow-up time was found. For every point of increase of the 
DBMA total score, there is a 7 % increased risk of death after four years. The Cox analysis 
was repeated without taking into account the correction for complex samples, because of 
the few deaths that took place in the ELES-PS ‘healthy’ community-dwelling population. 
After correction, the HR remained practically the same, but the p-value, which was on the 
border of significance, decreased to 0.002. This confirms that the higher p-value of 0.044 
was because of the decreased sample size that resulted from the correction for complex 
samples.  
 
The Kaplan-Meier curve showed a higher mortality rate among the highest DBMA 
categories. The difference between low DBMA scores (0-2) and the rest of score categories 
was especially pronounced. These findings support the association found in the Cox 
analysis. Finally, the area under the ROC was 0.803, which implies that the model can be 
regarded as moderately predictive (89). This confirms that the DBMA may be used as a 
predictor of mortality, and adds information about the applicability of the DBMA. 
 
In this study, apart from descriptive statistics of ELES-PS data, data from the Spanish 
Population and Housing Census and the Spanish National Health Survey were presented, 
as well as national mortality rates.  The participants in our sample showed higher 
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perceived health and the mortality rate found among its participants was way lower than 
the expected. This confirms once again that the ELES-PS sample was relatively healthy in 
comparison to the general population. Nonetheless, it is possible that the mortality rate 
was slightly underestimated because of matching errors between the ELES-PS database 
and the Ministry of Health’s. The search was repeated manually in order to avoid this, but 
it is not guaranteed that no other case was missed.  
 
It was not possible to compare the associations that were for found for the DBMA with 
those of another multimorbidity assessment instrument (concurrent validity), since no 
other multimorbidity measures were included in the ELES-PS survey. Comparisons with 
the CCI were performed before for the association with patient-centered and utilization 
outcomes, showing that the DBMA was more related to the former and less to the latter 
than the CCI (41,46), but it would be interesting to compare its performance predicting 
mortality. Further research should include this comparison with other multimorbidity 
tools which would facilitate the selection of the most appropriate instrument depending 
on the outcomes of interest.  
 
Briefly, Study 2 found significant relations between the DBMA and patient-centered 
outcomes, the system-centered variable of healthcare utilization and mortality. Although 
not assessed in the current study, previous research showed the CCI to be less related to 
patient-centered outcomes and more related to healthcare utilization than the DBMA.  
This implies that when choosing a comorbidity assessment instrument, this should be 
done according to the outcome of interest. If the outcome of interest is patient-centered, 
such as QoL, results of the current and previous studies suggest that the DBMA would be a 
good option. 
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Women showed not only higher disease prevalences but also higher disease burden scores 
per condition. According to these findings, interventions to improve QoL among 
multimorbid patients should put a special focus on women.  The DBMA might be applied to 
identify other groups of patients with high disease burden relative to their disease 
prevalences, such as groups according to income, educational level, or certain 
combinations of conditions.  
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5.3. STUDY 3: RASCH ANALYSIS 
 
Study 3 analyzed the measurement properties of the DMBA according to the Rasch model. 
Rasch analysis provides knowledge of psychometric attributes that are not assessed with 
CTT: test of fit to the Rasch model, response dependency, category structure, DIF and scale 
targeting. Other attributes, namely reliability and unidimensionality are assessed in both 
approaches but in a different manner. Moreover, Rasch analysis provides a linear measure, 
which allows calculation of change scores and, given a normal distribution, the use of 
parametric statistics (57,128). 
 
The Rasch analysis was performed with a randomly selected subsample of 300, since 
analysis with samples larger than 300 could result in statistically significant deviations 
from the Rasch model of otherwise well-fitting items. Linacre (64) stated about this: 
 If the test involves less than 30 observations, it is probably too insensitive, i.e., "everything 
fits". If there are more than 300 observations, it is probably too sensitive, i.e.,"everything 
misfits". 
This was also explained in an article published by Smith et al. (66): some Rasch fit 
statistics for polytomous scales are highly dependent on sample size, which translates into 
a higher possibility for type I errors with an increased sample size. Other studies used 
subsamples for the same reason (65,129). In order to compare the subsample with the 
total sample, descriptive statistics of both samples were paralleled, as well as the logit 
estimations of the two samples (300 vs. 1100) for each raw-score. In addition, a DIF 
analysis with the sample as a factor was performed. According to these comparisons, the 
subsample did not significantly differ from the total sample, meaning that the subsample 
forms an unbiased representation of the total sample.  
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 To achieve an adequate fit to the Rasch model, items needed to be rescored. This might 
have been due to too many response categories, which could have prevented people from 
making fine distinctions between rating scale steps. Another possible cause is the fact that 
the middle response options were not labeled. In most cases, response options were 
reduced to three categories. This reduction in response categories does not require 
changing the original questionnaire. Instead, it may be performed when calculating the 
total scores, thus avoiding using different response categories that could be confusing to 
the respondent. It would be interesting to study whether simplifying the questionnaire, by 
reducing the response categories in the same way for all items, would improve the 
psychometric properties of the DBMA. However, this might reduce the scale precision. 
Labeling the middle response options may also improve category structure. Further 
research is needed to confirm the response structure.  
 
The residual correlation index did not identify response dependency, meaning that there 
were no items linked in such way that the response to one item would determine the 
response to another. The residual correlations of the items of the DBMA were all far below 
the cut-off point, so no items needed to be combined.  
 
Four items displayed DIF by sex, indicating that men and women, despite having the same 
level of burden caused by hypertension, anxiety, osteoporosis or urinary tract problems, 
answered differently to these items. A very strict approach would have been to delete 
these items; however, this would have compromised the clinical applicability of the scale. 
Another possibility would be to split the items and get different calibrations for men and 
women (59). This would make the scale more difficult to score, which, nonetheless, is 
justifiable if DIF results are replicated in further studies. DIF was no longer present in the 
top-down purification analysis, meaning that if DIF favors men for one item, to balance 
women are favored for another item. So, for the moment, and taking into consideration 
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that differences were of small magnitude, a conservative attitude was followed by 
avoiding scale modifications due to DIF. DIF did probably not influence the sex differences 
found in this study, since DIF refers to group differences at the same construct level. 
 
The high floor effect was already discussed in the part of the discussion about the CTT. In 
Study 3, in which the total study sample was used, the floor effect was even more 
pronounced, as can be observed when comparing the distribution figures of both samples. 
As a consequence, a very asymmetrical person-item threshold distribution was found.  
Test performance would probably improve in a hospital-based sample, with a higher 
proportion of multimorbid patients and therefore less floor effects and better scale 
targeting. 
 
RUMM2030 showed low reliability and although the PSI value improved when using 
RUMM2020, it still did not fit the criterion. This result is quite surprising since Cronbach´s 
alpha in the first study did fit the criterion. PSI and Cronbach´s alpha are interpreted in the 
same way and measure the extent to which the items measure the same construct. 
However, when distributions are skewed, the PSI gives a more accurate indication of 
internal consistency reliability (130). In the DBMA, disease burden is rated for single 
diseases. This makes items in the DBMA less related to each other than in ‘regular’ 
psychometric scales. However, the items do measure the same construct, i.e. disease 
burden. PSI in RUMM2020 is less influenced by floor effects than in RUMM2030, and was 
probably therefore closer to the criterion of >0.70. This could also make us expect the PSI 
to be higher in a sample with more multimorbidity. Low PSIs were also found in other 
widely used scales, such as the EQ-5D-3D (131). 
 
According to the PCA, the DBMA was unidimensional. This result does not coincide with 
the exploratory factor analysis, which indentified five factors. In line with the literature, in 
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this case Rasch analysis provides superior results (132). The factor analysis was an 
exploratory analysis and was performed with the raw summative scores. Since these 
observations are non-linear, they can generate illusory factors (133). Moreover, in factor 
analysis items clustering at different performance levels are usually reported as different 
factors. Therefore, from factor analysis alone there is no way of knowing whether each 
factor is a dimension or part of a shared dimension. Although it makes sense to divide 
items into disease groups, the objective of the DBMA is to quantify disease burden caused 
by a series of different conditions on the whole and not per disease group.  
 
The Rasch analysis provided a linear measure. Moderate correlations between the linear 
measure and physical functioning, perceived health and depression were found and, as 
well as a weak correlation with QoL. These correlations are lower than the correlations 
found in Study 1 and 2, which can be ascribed to the fact that a different sample was used 
in Study 3, with younger participants and an even higher health status. The relative 
precision analysis displayed some gain in precision in discriminating between age groups 
but when discriminating between men and women, no difference was found with the 
original scale. These data suggest that the linear measure is at least as valid as the raw 
summative score concerning discriminant validity. 
 
The linear measure showed a peculiar distribution, due to the distances between lower 
DBMA scores: a raw score of 1 was converted into a linear score of 4.46; a raw score of 2 
was converted into a linear value of 7.44. Moreover, RUMM2030 calculated parameter 
estimations for observations with missing values that did not coincide with the scores in 
the conversion table. The large distances between the lower scores can be interpreted in 
the following way: the difference in disease burden between raw scores of 0 and 1 is much 
bigger than the difference in disease burden between raw scores of 9 and 10. This can be 
illustrated with the classical example of studying for an exam: when using a 1-10 grading 
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system, it does not require the same amount of study time to pass from 0 to 1 (or 9 to 10) 
as to pass from 4 to 5. The same is the case for the response options of the DBMA. 
 
Does this mean that from now on, when using the DBMA, the linear measure should be 
calculated? This depends on the context in which the DBMA is used. One of the main 
advantages of the DBMA is its simplicity.  It repeats the same question for only the present 
conditions in a person which makes that it is very little time-consuming. The same is the 
case for the interpretation of the DBMA, which consists in simply summing the scores 
given to the individual conditions. Having to convert the summative score into a linear 
measure would make this process more complicated. Conversely, one of the advantages of 
a linear measure is that it allows the use of parametric statistics, given a normal 
distribution. In case of the DBMA, distributions will usually be skewed, even in study 
populations with high multimorbidity levels (45). Another advantage is that is allows to 
calculate change scores. The reason why this cannot be done with the raw score is because 
the measurement intervals between the response options are unequal (134), as explained 
above. Since these distances are unequal, the change in disease burden over time cannot 
be quantified because one point change does not always mean the same increase in 
disease burden along the construct continuum. Taking into account these advantages and 
disadvantages, it can be concluded that when calculating change scores, the linear 
measure should be applied. In other contexts, the raw summative score might be a good 
option.  
 
In conclusion, an adequate fit to the Rasch model was achieved after rescoring the 
response options. Rasch analysis found the DBMA to be unidimensional and neither 
response dependency nor relevant DIF were found. The absence of DIF means that 
individuals with the same level of disease burden do not have different probabilities of 
attaining a certain score on the item. Scale targeting was below standards, with an 
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asymmetrical patient distribution and reliability was low. Further research in a hospital-
based sample is proposed, in which the last two parameters are expected to improve. 
Rasch analysis provided a linear measure that permits the calculation of change scores. 
This makes the linear measure useful for clinical follow-up of patients as well as for 
comparisons before and after interventions to improve QoL in multimorbid patients.   
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5.4. LIMITATIONS AND STRENGTHS 
 
5.4.1. LIMITATIONS 
 
Some limitations should be acknowledged. Analyses in the first study were not corrected 
for complex samples or weights, since this would impede some of the feasibility and 
acceptability analyses. Rasch analysis does not permit correcting for complex samples or 
weights either, so in the third study, the uncorrected data were also used. Thus, results in 
these studies cannot be extrapolated to the Spanish population as a whole and cannot be 
compared with data in the second study.  
 
Furthermore, as in other studies (45,47,48), the list of conditions included in the DBMA 
was adapted in the ELES-PS, which hinders comparisons across studies. Bayliss et al. (45) 
found a mean disease burden score of 20 in one of their studies, a value much higher that 
the mean score in the ELES-PS sample. However, since different lists of chronic conditions 
were used, these mean values are not comparable. A standard list of conditions should be 
developed for future use.  
 
A third limitation was that it was not possible to study concurrent validity (the relation of 
the scale with other tests) since no other measures of multimorbidity or disease burden 
were included in the ELES-PS.  Other authors compared the performance of the DBMA 
with the CCI, RxRisk score, Quan comorbidity index, CDS and CIRS (41,45,47), all with 
satisfactory results. It would have been of special interest to compare the DBMA as a 
predictor of mortality with another comorbidity index that was specifically validated to 
predict mortality, such as the CCI or the ECM.  
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Fourthly, as discussed before, a very healthy sample was used to validate a disease burden 
assessment. The ELES-PS sample showed a higher health status than the general Spanish 
population, as shown in Study 2. As a result, very high floor effects and a skewed 
distribution were found in Study 1. Study 2 showed a very low mortality rate and in Study 
3 a very low PSI and an asymmetrical person-item threshold distribution were found. In a 
hospital-based sample, with higher multimorbidity and burden, these parameters would 
probably improve. 
 
Fifthly and finally, the four-year follow-up time for mortality was quite short, especially 
given the high health status of the participants in the ELES-PS. Only 5.5% of the 
participants in the sample used in Study 2 had died, which led to limited statistical power 
in the predictive validity analyses. The same database might be used to repeat the 
analysed in future research, after a longer follow-up time.  
 
5.4.2. STRENGHTS 
 
This work used the data of a national survey, with a sample designed to be representative 
of the elderly population in Spain. Since the Study 2analyses were corrected for complex 
samples its generalizability to the general population is higher. The ELES-PS included a 
great variety of measures and indices, making it possible to assess the DBMA convergent 
validity with different self-reported outcomes. Moreover, it was possible to study the 
association with mortality, whose data were manually crossed with those of the National 
Death Index. Finally, this work consists of a quite complete psychometric validation, 
including a Rasch perspective. Rasch analysis cannot be performed in regular statistic 
programs such as Stata or SPSS and requires specific software and statistical expertise. It 
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evaluates psychometric attributes, such as DIF and category structure, that are not 
included in the CTT approach and provides a linear measure, with important advantages.  
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5.5. STUDY IMPLICATIONS 
 
The DBMA is a scale that measures the subjective disease severity of 21 common chronic 
conditions. It repeats the same question for only present conditions, and due to this simple 
design, as well as being easy to understand and short administration time, it is especially 
useful for use in the older population.  
 
Multimorbidity is an important public health problem and an essential aspect of care for 
chronically ill persons is to maximize their QoL. Different methods of measuring 
multimorbidity are associated with different health outcomes, and the choice of 
instrument depends on the outcome of interest. The DBMA has shown to be especially 
related to patient-centered outcomes as QoL and physical functioning, although it also 
showed significant relations with healthcare utilization and mortality.  
 
The DBMA might be used in individual patients to assess and follow-up disease burden by 
chronic conditions. The scale may also be applied to identify patient groups with high 
disease burden for posterior interventions as well as the evaluation of these interventions. 
Some examples are interventions to improve QoL and functional status in multimorbid 
patients, such as self-management interventions, home care programs, or group meetings 
for chronically ill persons (135–137). The linear measure, as a result of the Rasch analysis 
in this work, may be applied for the calculation of change scores in these evaluations.  
 
This work also identified areas for further research. Different psychometric parameters 
were expected to improve in hospital-based samples with more multimorbidity, such as 
floor effects, ITCC, scale targeting and reliability (PSI). Furthermore, the response scale 
structure should be confirmed in further research, and it would be interesting to also use a 
multimorbid population for this purpose. As stated in the limitations section, until now, 
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different authors have used different lists of conditions in the DBMA.  A standard list of 
conditions should be developed in order to make results comparable across studies. 
Finally, to be able to choose the most suitable multimorbidity assessment instrument 
depending on the outcome of interest, a comparison of the DBMA with other 
multimorbidity measures in predicting mortality is suggested, which was not possible in 
the current research. Again, it would be interesting to do this in a less healthy sample, to 
find higher mortality rates, for which a longer follow-up time would be another valid 
option. 
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6. CONCLUSIONS 
 
1. The DBMA consists of a list of chronic medical conditions from which respondents 
select the conditions they have. Limitations on daily life are rated on a scale from 1 to 
5 for present conditions and non-present conditions are scored 0. Due to this design, 
the DBMA shows high floor effects per item, even in comorbid populations, since they 
reflect all absent conditions.  
 
2. Scoring high for one condition does not mean the other conditions should be present 
as well. Therefore, items are not highly related to each other nor to the total score (low 
item homogeneity index and item-total correlations). There were no items linked in 
such way that the response to one item would determine the response to another 
(response dependency).  
 
3. The DBMA was designed and validated to be associated with patient-centered 
outcomes. This was confirmed in this work: it showed satisfactory convergent validity 
with physical functioning, perceived health, depression, QoL and affect balance.  
 
4. A positive association between the DBMA and healthcare use was found. The 
performance of the DBMA as a predictor of mortality had not been studied before and 
a positive association was found, despite the low mortality rate in the used sample. 
 
5. Women scored higher on the DBMA not only because they had more present 
conditions, but also because they reported higher disease burden per condition. There 
were also differences by age, though less pronounced. 
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6. Exploratory factor analysis suggested the presence of five dimensions according to 
disease groups within the DBMA. However, Rasch analysis confirmed the scale to be 
unidimensional. The DBMA measures one dimension, namely the impact of chronic 
conditions on daily life, conceptualized as disease burden. 
 
7. Reliability was satisfactory in CTT (Cronbach’s alpha) but below standards in Rasch 
analysis (PSI). The high health status in the used sample might have played a role in 
this and further research is needed.  
 
8. The participants were not able to make fine distinctions between response options 
(category structure), and rescoring of response options is proposed by Rasch analysis. 
 
9. No relevant DIF was found for age, sex and educational level, meaning that persons 
belonging to different groups, with the same level of disease burden, did not rate their 
disease burden differently. 
 
10. Rasch analysis provided a linear measure that should be used when calculating change 
scores.  
 
 
 
In summary, results suggest that, despite some limitations such as reliability below the 
expected and high floor effects, the DBMA is an adequate patient-reported health outcome 
for measuring disease burden caused by 21 common chronic diseases in older adults. 
Persons with multiple chronic medical conditions are progressively becoming more 
common in our healthcare systems, and it is important to assess the impact that patients 
themselves experience because of their multimorbidity. The DBMA measures the burden 
of multimorbidity, by simply asking the patient to rate the impact of diseases on what is 
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most important to the patients themselves: everyday life. It is an easy-to-use tool that can 
contribute to the implementation of strategies to improve QoL and functional status for 
the growing group of older patients with multiple chronic conditions.  
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Disease burden morbidity assessment by self-report:
Psychometric properties in older adults in Spain
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Aim: To carry out an analysis of the psychometric properties of the Disease Burden Morbidity Assessment (DBMA)
according to the assumptions of the Classical Test Theory.
Methods: A sample of 707 community-dwelling adults aged 65years and older, living in Spain, completed the DBMA.
Psychometric properties of the scale (feasibility, acceptability, scaling assumptions, reliability and construct validity) were
analyzed.
Results: The mean DBMA score was 6.8. Feasibility and acceptability were satisfactory, except for large ﬂoor effects
(>50%), as well as a skewed distribution (1.8). Item-total corrected correlation ranged 0.10–0.49, item homogeneity index
was 0.09 and Cronbach’s alpha was 0.72. Disease burden correlated strongly with physical functioning (r= –0.56) and
perceived health (r=–0.56), and moderately with depression (r=0.41) and the Personal Wellbeing Index (r=–0.41).
Exploratory factor analysis extracted ﬁve factors, explaining 44% of the variance.
Conclusions: The DBMA is an acceptable and valid instrument for measuring disease burden in older adults. Future
studies should include Rasch analysis to further assess dimensionality and explore other measurement properties.Geriatr
Gerontol 2016; ••: ••–••
Keywords: aged, burden of illness, chronic disease, comorbidity, psychometrics.
Introduction
As chronic health conditions are more frequent among
older people, the process of population aging will further
increase the prevalence of these, as well as the prevalence
of co- and multimorbidity.1 The terms co- and
multimorbidity both refer to the presence of multiple
chronic conditions in one person, but in the case of
comorbidity, these are studied from the perspective of
one index-disease.2 The term,multimorbidity, is currently
preferred when referring to measures of chronic health
conditions, and will therefore be used in this study,
although both terms could be used interchangeably.
Multimorbidity is a frequent phenomenon in elderly
populations, with an estimated prevalence ranging from
55 to 98% in persons aged 65years and older.3 It is an
important prognostic factor, with well-described negative
effects on mortality, complications, surgical outcome and
hospital length of stay,4 and a direct and independent
effect on disability and quality of life (QoL).5
TheCharlson Comorbidity Index6 and the Elixhauser’s
comorbidity tool7 are two widely applied tools for
multimorbidity risk adjustment. Both scales weigh disease
categories based on the associated risk of mortality.
However, these tools do not assess disease severity, and
studies have shown that the incorporation of severity
assessment signiﬁcantly improves the predictive value of
morbidity measures.4,8
Bayliss et al. developed a multimorbidity scale, the
Disease Burden Morbidity Assessment (DBMA) that
assesses the impact of 23 conditions on daily activities as
a measure of disease severity, conceptualized as
self-reported disease burden.9 This scale was designed in
order to create a subjective measure of comorbidity, to
be used especially in studies using QoL outcomes, where
the patient’s perception plays an important role. The
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developing authors carried out an initial validation of this
scale in older adults, calculating sensitivities and speciﬁc-
ities relative to chart review, and assessing convergent
validity of the DBMA with QoL outcomes. In following
studies, the association between the DBMA and
biopsychosocial factors were analyzed.10–12 Poitras et al.
validated the DBMA in French, and assessed test–retest
reliability and concurrent validity with the cumulative
illness rating scale.13
A complete analysis of psychometric properties,
following the steps of the Classical Test Theory, had
not been carried out yet. The aim of the present investi-
gation was to complement the validation process by
studying these properties in a sample of older adults. A
secondary goal was to assess the performance of this
scale in Spanish. To the best of our knowledge, this is
the ﬁrst publication about this scale applied to a
Spanish-speaking population, and adds information
about the use of the DBMA in a different language
and cultural setting.
Methods
Study design
Data were extracted from the Aging in Spain Longitudinal
Study, Pilot Survey (ELES-PS). This study was carried out
in 2011 among community-dwelling adults aged 50years
or older, living in Spain. Representative participants were
randomly selected on a national geographic basis, in three
stages. First, stratiﬁed clusters were formed by autono-
mous region and municipality size, proportionally to its
population aged 50years and older. Second stage units
consisted of households with telephone lines that were
selected from census data. Finally, a random selection of
individuals was carried out from each household, with
post-stratiﬁcation by sex and age group (50–59, 60–69,
70–79 and 80–89years). People from the Basque region
were overrepresented in the sample.
Data were collected in four phases: a telephone
questionnaire, a visit by trained nurses, a Computer-
Assisted Personal Interviewing (CAPI) questionnaire
and a self-administered questionnaire. The DBMA was
included in the CAPI questionnaire, applied to 1400
persons. As this scale was originally developed to be
used in older adults, we selected a subsample of persons
aged 65years and older, resulting in a ﬁnal sample of
707 persons.
The CAPI interviews took place at the respondents’
homes, and were carried out by a trained interviewer. In
the case of cognitive impairment, the interviewwas carried
out with a proxy respondent, excluding in this case the
questions that required a subjective judgement. Questions
about sensitive subjects, such as sex life and depression,
were administered through the self-administered
questionnaire.
Assessments
Weapplied a scale consisting of a list of 21medical diagno-
ses of chronic conditions whose severity was scored
following the procedure of the DBMA instrument
described by Bayliss et al.9 Participants were asked for
every condition whether they had it, and if so, to what
extent these conditions limited their everyday activities
on a scale from 1 (“not at all”) to 5 (“a lot”). Non-present
conditions were scored 0. The DBMA total score,
representing the level of self-reported disease burden,
was a result of the sum of the limitation levels assigned
to the 21 conditions.
As in other studies,12–14 we adapted the original
DBMA’s 23-item list, based on the conditions used in
other multimorbidity indices.4,9,15–17 From the publica-
tions in which analysis per condition had been carried
out, we selected those conditions that speciﬁcally pre-
dicted mortality, hospitalization or future handicaps and
those that showed a transversal association with physical
functioning.15–17 In the case where analysis per condition
had not been carried out, all conditions were selected.4,9
As a criterion, only conditions selected from more than
one index were included. A few exceptions were made:
liver diseases were not included because of their low
prevalence, and urinary tract conditions, anxiety and
memory-related disorders were added because of their
high prevalence in older adults.
To screen for depression, a dichotomous 10-item
Center for Epidemiologic Studies Depression Scale was
administered through the self-administered question-
naire.18 This scale was validated for the Spanish-speaking
population, and has shown to be a valid instrument for
detecting major depression in older adults. It contains 10
questions with “yes/no” response categories, and a score
of 1 is assigned for every positive answer for depression. A
sum score of 3 was used as a cut-off point for depression.
A 24-item scale, as used in the Health and Retirement
Study, was included in the CAPI questionnaire as ameasure
of physical functioning.19 This scale consists of a list of 24
different activities (e.g. getting dressed, walking 100m and
making phone calls) and participants are askedwhether they
experience difﬁculties when carrying them out, on a scale
from 1 (always) to 4 (never). Scores were summed in order
to obtain a measure of physical functioning.
QoLwas assessed through the PersonalWellbeing Index
(PWI),20 included in the CAPI-questionnaire, in which
respondents are asked to grade, on a scale of 1 to 10, their
satisfaction with seven life dimensions: standard of living,
personal health, achieving in life, personal relationships,
personal safety, community-connectedness and future
security. Total subscores were lineally transformed into a
0–100 scale, and higher total scores indicate better QoL.21
The second dimension of the PWI, grading personal health
on a scale of 1 to 10, was used as a measure of perceived
health.
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Data analysis
We examined the following psychometric properties:
feasibility, acceptability, scaling assumptions, reliability and
construct validity. Feasibility was assessed by determining
the percentage ofmissing values per item and the percentage
of computable scores for the total scale, considering accept-
able scores <10% and >90%, respectively.22 Acceptability
was explored by comparing possible and observed scores,
and assessing mean-to-median difference for the total scale
(criterion, <10% of the scale range) as well as ﬂoor and
ceiling effects (<15%) and skewness (–1 to 1).23
Scaling assumptions were determined through the
item-total corrected correlation for each item (criterion
r≥0.40).24 Reliability was assessed through internal
consistency (Cronbach’s alpha) and the item homogeneity
index (criteria: α≥0.70 and r ≥0.30, respectively).22
For convergent validity, we expected self-reported
disease burden to be negatively associated with perceived
health, physical functioning and QoL, and to ﬁnd a
positive association with depression.1,5,25 This was calcu-
lated through Spearman’s rank correlation coefﬁcients
because of the non-normal distribution. Correlation coef-
ﬁcients were interpreted following Cohen’s conventions,
considering correlations ≥0.5 large, 0.5–0.3 moderate
and 0.3–0.1 small magnitudes of effect.26 Spearman’s rank
correlations were repeated using the self-reported number
of conditions instead of disease burden, to evaluate the
added value of assessing the impact of conditions on daily
life. These correlations were compared using a Fisher’s
r-to-z transformation.27 Because the DBMA had a higher
number of missing values than the disease count variable,
we excluded those cases with missing values for DBMA in
this analysis in order to make the two variables compara-
ble. Known-groups validity was examined comparing
disease burden by sex and age groups (Wilcoxon rank-
sum test). As multimorbidity is more frequent in women
and older people, we hypothesized to ﬁnd signiﬁcantly
higher scores in these groups.28
Dimensionality and factor structure were explored
through exploratory factor analysis, using a principal axis
factoring method with oblimin rotation. The number of
extracted factors was determined according to eigenvalues
(>1) and visual inspection of the screeplot, taking the
“elbow” as the point of separation.29 All statistical analyses
were carried out using STATA 12 for Windows (StataCorp,
College Station, TX, USA).
Results
Table 1 presents descriptive statistics of sociodemographic
data and applied rating scales. The mean age of the partic-
ipants was 74.2years (standard deviation [SD] 6.6), and
57.0%were women. Mean 10-item Center for Epidemio-
logic Studies Depression Scale score was 2.0 (SD 2.3) and,
according to this scale, depressionwas present in 30.3%of
the participants who answered the self-administered ques-
tionnaire. More than half of the participants (50.9%,
n=360) reported having three ormore chronic conditions,
the average number of conditions being 3.2 (SD 2.4).
Mean DBMA score was 6.8 (SD 7.1).
Hypertension was the most frequent chronic health
condition (n=339, 48.1%), and also the condition with
the lowest mean disease burden score (mean score 1.5,
SD0.9; Table 2). Parkinson’s diseasewas the least frequent
condition (n=12, 1.7%). The highest mean disease bur-
den score was found for chronic back pain (2.9, SD 1.2)
and myocardial infarction (2.9, SD 1.2).
All items had less than 4%missing responses, and the per-
centage of computable scores for the total scale was 88.4%.
The observed and possible range was 0–5 for all items, with a
median score of 0. The median for the total scale was 5, with
a mean–median difference of 1.7%. For all items, ﬂoor effects
wereabove50%andceilingeffectswerebelow3%.Whenonly
studying thepresent conditions, therewas still aﬂoor effect, but
less pronounced (range 14.1–66.8%). Skewness was 1.80.
Item-total corrected correlation was low for all condi-
tions (range 0.10–0.49). Cronbach’s alpha was 0.72, and
the item homogeneity index was 0.09.
Table 1 Characteristics of the study sample (n=707)
Characteristic (range) n (%)
Mean±SD
Sex Male 304 (43.0)
Female 403 (57.0)
Age (years) 74.2±6.6
Education Less than primary 365 (51.6)
Primary 137 (19.4)
Secondary 83 (11.7)
University 122 (17.3)
Living area <10000 inhabitants 133 (18.8)
10000–100000 inhabitants 273 (38.6)
100000–500000 inhabitants 201 (28.4)
>500000 inhabitants 100 (14.1)
Marital status Single 31 (4.4)
Married/living
with partner
439 (62.1)
Widowed 211 (29.8)
Divorced/separated 26 (3.7)
CES-D† Depression 159 (22.5)
No depression 366 (51.8)
Missing 182 (25.7)
Physical functioning (24–96) 88.3±11.8
PWI (0–100) 75.3±11.1
Satisfaction with health (0–10) 7.1±5.3
Self-reported number of conditions (0–21) 3.2±2.4
DBMA (0–105) 6.8±7.1
†Cut-off point: 3 out of 10. CES-D, Center for Epidemiologic
Studies Depression Scale; DBMA, Disease Burden Morbidity As-
sessment; PWI, Personal Wellbeing Index; SD, standard deviation.
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Data on convergent validity are shown in Table 3. The
DBMA had a correlation of –0.56 with physical function-
ing and perceived health, –0.41 with PWI and 0.41 with
depression. All correlations were signiﬁcantly stronger
for the DBMA than for the number of diseases. Women
had higher mean DBMA scores than men (8.4 vs 4.9,
P<0.001). Disease burden scores increased signiﬁcantly
with age, with a mean score of 6.1 in participants aged
<75years and 7.7 in participants aged ≥75years
(P<0.001). The exploratory factor analysis extracted ﬁve
factors (explained variance 43.6%): conditions of the
locomotor system (intermittent claudication, osteoarthri-
tis, rheumatoid arthritis, osteoporosis and chronic back
pain), depression/anxiety, cardiovascular diseases (myo-
cardial infarction, heart failure, angina, stroke), lung disor-
ders (asthma, COPD), and a mixed group of cancer and
renal/urinary tract diseases (kidney disease, cancer, urinary
tract problems). Five conditions did not ﬁt in any of the
factors: hypertension, diabetes, gastric/duodenal ulcer,
memory disorders and Parkinson’s disease.
Discussion
The present study analyzed the psychometric properties of
a Spanish version of the DBMA, and, despite some limita-
tions, it was found to be a valid and reliable tool for mea-
suring self-reported disease burden in older adults.
Previous studies had already carried out initial validations
of the DBMA. Bayliss et al. showed that the DBMA had
stronger correlations with QoL outcomes than two other
comorbidity measures, and found that median sensitivity
and speciﬁcity relative to chart review were 75% and
92%, respectively.9 Poitras et al. validated the DBMA in
French in a general population aged 18years and older,
and foundmoderate-to-large correlations with the cumu-
lative illness rating scale and a high test–retest reliability.13
As the DBMA repeats the same question and only for
the conditions a participant has, it is easier and less time-
consuming than other psychometric questionnaires.
However, this design also meant that some of the present
results did not meet the previously set criteria. Although
it does assess a psychometric construct; that is, the disease
burden that people experience as a result of their chronic
conditions, the 21 items in the DBMA were not designed
to be highly associated to each other, nor to the total score.
Therefore, it was not a surprise to ﬁnd a very low homoge-
neity index, and low item-total correlations. However,
internal consistency was satisfactory.
In addition, because of the low prevalence of most of
the conditions included in this questionnaire, a high value
for skewness and large ﬂoor effects were not surprising.
Floor effects were lower when only studying present
conditions, but remained high. Reformulating the
response scale options might attenuate this effect, and
Rasch analysis could be helpful for this purpose. The per-
centage of computable scores was just below standards.
The DBMA in the present study was part of a much larger
questionnaire, which might have inﬂuenced the willing-
ness and capability to answer the questions of the DBMA.
The DBMA was found to have a strong correlation
with physical functioning and perceived health, and
moderate correlations with depression and PWI. Bayliss
et al. reported similar associations, with comparable corre-
lations with physical functioning and self-reported health
status, and a lower correlation with depression.9,11,12 This
last difference can be explained by the fact that, unlike
Bayliss et al., we did include depression in the list of stud-
ied conditions. Depression is a frequent condition and
an important cause of disability,30,31 for which we consid-
ered it essential to be included in the DBMA, as was also
done by Poitras et al.13
ELES-PS data conﬁrmed that the DBMA is more
strongly associated with depression, perceived health and
physical functioning than the number of conditions,
although these differences were less pronounced than in
the study published by Bayliss et al.9 This outcome is of
interest because although the DBMA is a relatively short
questionnaire, it is still more laborious than a simple
disease count. The association between a simple count
of chronic conditions as a measure of multimorbidity
andQoL has widely been studied.32,33 However, measures
taking into account disease severity seem to be better
predictors of QoL, as was conﬁrmed in the present
study.34 The relationship between the DBMA and the
PWI had not been studied yet, and the present study has
found a moderate correlation. Some of the dimensions
of this scale are not directly related to health, such as per-
sonal safety and future security,20 and the correlation with
Table 3 Convergent validity: Spearman’s rank correlation coefﬁcients of the self-reported number of conditions and
Disease Burden Morbidity Assessment with other health-related measurements
No. conditions DBMA P-level for correlation difference
Depression, CES-D (n=474) 0.35* 0.41* 0.0043
Physical functioning (n=596) –0.51* –0.56* 0.0010
Quality of Life, PWI (n=540) –0.35* –0.41* 0.0006
Perceived health (n=625) –0.51* –0.56* 0.0035
*P< 0.001. CES-D, Center for Epidemiologic Studies Depression Scale; DBMA, Disease BurdenMorbidity Assessment; PWI, Personal
Wellbeing Index.
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a scale measuring health-related QoL could possibly be
stronger.
The factor analysis identiﬁed known disease groups.
Intermittent claudication is a motor symptom and there-
fore it was probably more related to musculoskeletal
disorders than to cardiovascular diseases.
Some limitations should be acknowledged. As the
sample used for this validation study contained a subsam-
ple from the Basque Country, results cannot be extrapo-
lated to the Spanish population as a whole. Weighing the
sample to correct for this overrepresentation would have
been the most appropriate solution, but impeded some
of the feasibility and acceptability analyses. Also, as no
other comorbidity indexes were included in the ELES-
PS, we could not analyze convergent validity with other
more widely used comorbidity tools. Furthermore, as in
other studies, we adapted the list of conditions included
in the DBMA, which hinders comparisons across
studies.12–14 A standard list of conditions should be
developed for future use.
In conclusion, the DBMA has shown to be a valid and
easy-to-use instrument for measuring disease burden. As
this scale provides a subjective measure of multimorbidity,
it is particularly useful for investigations using QoL
outcomes. Future research should include a Rasch analy-
sis in order to further study the scale’s dimensionality and
to explore other measurement properties.
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Abstract
Purpose of the Study: The Disease Burden Morbidity Assessment (DBMA) is a self-report questionnaire in which partici-
pants rate the disease burden caused by a number of medical conditions. This paper studies the measurement properties of 
the DBMA, using Rasch analysis.
Design and Methods: We used data of 1,400 community-dwelling adults aged 50 years and older participating in the 
Ageing in Spain Longitudinal Study, Pilot Survey (ELES-PS). Test of fit to the Rasch model, reliability, unidimensionality, 
response dependency, category structure, scale targeting, and differential item functioning (DIF) were studied in an iterative 
way. Construct validity of the linear measure provided by the Rasch analysis was subsequently assessed.
Results: To achieve an adequate fit to the Rasch model, all items were rescored by collapsing response categories. Reliability 
(Person Separation Index) was low. The scale was unidimensional and neither response dependency nor relevant DIF were 
found. The linear measure had a correlation of −0.48 with physical functioning, −0.47 with perceived health, 0.32 with 
depression, and −0.24 with quality of life (QoL) and displayed satisfactory known-groups validity by sex and age groups. 
Relative precision analysis showed that the linear measure discriminated better between age groups than the original raw 
score, but for sex no difference was found.
Implications: Despite some limitations, support was found for the validity of the DBMA in older adults. Its linear scores 
may be useful to assess strategies aimed at improving the QoL of patients with multimorbidity. More research is needed in 
a hospital-based sample.
Keywords:  Burden of Illness, Chronic disease, Comorbidity
The ageing of populations is a global phenomenon (Beard, 
Officer, & Cassels, 2016). In 1950, the worldwide propor-
tion of persons aged 60 years and older was 8% (United 
Nations, Department of Economic and Social Affairs, 
Population Division, 2013). This percentage rose to almost 
12% in the year 2013, and is expected to reach 21% in the 
year 2050. In high-income countries, these rates are even 
higher, with almost 23% in the year 2013 and a prediction 
of 32% for the year 2050. As a consequence, the preva-
lence of multimorbidity, that is, the presence of multiple 
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coexisting chronic conditions in one person, will also con-
tinue to increase (Gijsen et al., 2001). Multimorbidity is a 
worldwide health problem with well-described associations 
with mortality, complications of treatment, health care 
utilization, and a negative effect on quality of life (QoL) 
(Barnett et al., 2012; Fortin et al., 2004; Gijsen et al., 2001; 
Sangha, Stucki, Liang, Fossel, & Katz, 2003). It requires a 
different health care approach, with a more holistic view of 
patients instead of treating single diseases (Fortin, Stewart, 
Poitras, Almirall, & Maddocks, 2012).
There are different tools to assess multimorbidity, and 
the choice of instrument depends on the methodology and 
outcomes of the investigation (Bayliss, Ellis, & Steiner, 
2009). Several studies have shown the importance of 
assessing subjective disease severity when studying multi-
morbidity, especially in relation to QoL outcomes (Byles, 
D’Este, Parkinson, O’Connell, & Treloar, 2005; Crabtree, 
Gray, Hildreth, O’Connell, & Brown, 2000; Sangha et al., 
2003). Therefore, Bayliss, Ellis, and Steiner (2005) created 
a patient-reported outcome measure in which patients 
select chronic conditions from a list and then rate their 
impact on everyday activities as a measure of disease sever-
ity. This was conceptualized as self-reported disease bur-
den. Disease burden can be defined as the impact of disease 
events on various dimensions of human life (Pinheiro, Plaß, 
& Krämer, 2011), in this case the subjective interference 
with daily activities. The tool was subsequently denomi-
nated the Disease Burden Morbidity Assessment (DBMA) 
by Poitras, Fortin, Hudon, Haggerty, and Almirall (2012).
After an initial validation according to the classical test 
theory, including an exploratory factor analysis (Wijers 
et al., 2016), an additional step in the validation process 
would be an analysis following the item response theory. 
The aim of this study was to perform this through a Rasch 
analysis (Rasch, 1980). Rasch analysis allows us to study 
scale attributes such as unidimensionality, response cat-
egory ordering, local independence of items, item bias by 
specific groups, and scale targeting, and provides a linear 
measure, which, given an appropriate distribution, permits 
the use of parametric statistics (Forjaz et al., 2012).
Methods
Study Design and Sample
Data came from the Ageing in Spain Longitudinal Study, Pilot 
Survey (ELES-PS), which included 1,747 community-dwelling 
adults aged 50 or more, living in Spain (Teófilo Rodríguez, 
González Cabezas, Díaz Veiga, & Rodríguez Rodríguez, 
2011). For the sampling, stratified clusters of census sections 
were randomly selected by autonomous region and municipal-
ity, proportionally to their population of 50 years and older. 
Households with a telephone line were selected at random 
from a commercial household telephone directory. Per house-
hold, individuals aged 50 or more were randomly selected, 
with post-stratification by sex and age group (50–59, 60–69, 
70–79, and 80–89 years). Field work was conducted in 2011.
The data in the ELES-PS study were collected in four 
stages: a telephone questionnaire (n = 1,747), a visit by a 
trained nurse (n  =  1,531), a Computer-Assisted Personal 
Interviewing (CAPI) questionnaire (n = 1,400), and a self-
administered questionnaire (n = 1,145). DBMA data were 
collected through the CAPI questionnaire, and its 1,400 
participants formed the sample that was used for the cur-
rent study. For the Rasch analysis, a random subsample of 
300 was taken, since analysis with samples larger than 300 
could result in statistically significant deviations from the 
Rasch model of otherwise well-fitting items (Linacre, 1994, 
2016; Mavranezouli, Brazier, Young, & Barkham, 2011; 
Smith, Rush, Fallowfield, Velikova, & Sharpe, 2008).
Descriptive statistics of sociodemographic data and 
applied rating scales of the total sample and the subsample 
are displayed in Table 1. Mean age of the participants in the 
total sample was 65.5 (standard deviation [SD] = 10.40) 
years, and 55.36% of them were women. The mean num-
ber of self-reported diseases was 2.5 (SD  =  2.25), and a 
mean raw DBMA score of 5.29 (SD = 6.39) was found.
Assessments
The DBMA, first described by Bayliss and colleagues (2005), 
consists of a self-report questionnaire in which participants 
rate the disease burden caused by a number of medical con-
ditions, if present. Patients are asked to what extent condi-
tions interfere with daily activities, on a 5-point scale from 
1 (not at all) to 5 (a lot). Conditions not present are scored 
zero. We adapted the list of conditions included by Bayliss 
and colleagues by selecting 21 common chronic conditions, 
according to their use in other multimorbidity indexes 
(Bayliss et  al., 2005; Byles et  al., 2005; Fried, Bandeen-
Roche, Kasper, & Guralnik, 1999; Groll, To, Bombardier, 
& Wright, 2005; Sangha et al., 2003). More detailed infor-
mation about how the 21 included conditions were selected 
may be found elsewhere (Wijers et al., 2016).
To measure physical functioning, a 24-item list of dif-
ferent basic and instrumental activities of daily living, as 
used in the Health and Retirement Study (Bendayan et al., 
2016), was applied. Participants were asked whether they 
experience difficulties when performing these activities on 
a scale from 1 (always) to 4 (never). Higher scores indicate 
better physical functioning.
A dichotomous, self-administered 10-item Center for 
Epidemiological Studies-Depression (CES-D) scale was 
used to screen for depression cases (scores of 3+) (Robison, 
Gruman, Gaztambide, & Blank, 2002). Previous studies 
found support for this short version of the CES-D to be 
as reliable as the original CES-D, with a Cronbach’s alpha 
of 0.80, and to show satisfactory convergent validity with 
the Composite International Diagnostic Interview (sensitiv-
ity and specificity of 84% and 64%, respectively) (Irwin, 
Artin, & Oxman, 1999; Robison et al., 2002).
For QoL, the CAPI questionnaire contained the Personal 
Wellbeing Index (PWI) (The International Wellbeing Group, 
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2013). This scale consists of seven life dimensions rated on 
a 1–10 scale. Total scores were linearly transformed into a 
0–100 scale, higher scores indicating better QoL. Previous 
research found support for the validity and reliability of 
this linear measure in older adults, correlating moderately 
with “satisfaction with life” and showing a PSI of 0.91 
(Forjaz et al., 2012). The dimension “personal health” of 
the PWI was used as a measure of perceived health.
Statistical Analysis
Rasch analysis was performed using RUMM 2030. 
Differences between thresholds were not expected to be 
equal across items, so the Masters Partial Credit polyto-
mous model was chosen (Masters, 1982), which was con-
firmed by a significant likelihood ratio statistic. Test of fit 
to the Rasch model, reliability, unidimensionality, response 
dependency, category structure, scale targeting, and dif-
ferential item functioning (DIF) were studied in an itera-
tive way, making model modifications until a good fit was 
achieved (Tennant & Conaghan, 2007).
Fit to the Rasch model was tested by comparing the 
observed data with the theoretical item performance 
according to the Rasch model. The item–trait interaction 
statistic, reported as a chi-square, needs to be nonsignifi-
cant (Tennant & Conaghan, 2007). Item and person sum-
mary fit statistics should follow a normal distribution with 
a mean and SD of approximately 0 and 1, respectively. 
Individual item and person standardize fit residuals should 
be within the ±2.5 range and chi-square differences for 
items and persons should be nonsignificant with Bonferroni 
correction for number of items (Pallant & Tennant, 2007).
Reliability was determined with the Person Separation 
Index (PSI), which is interpreted similarly to Cronbach’s 
coefficient alpha: a minimum value of 0.70 for group com-
parisons is recommended (Tennant & Conaghan, 2007). 
The PSI was also obtained in RUMM2020 since algo-
rithms derived from this program provide reliability results 
less influenced by extreme values, missing data, and floor 
and ceiling effects than those obtained with RUMM2030 
(Forjaz et al., 2015).
Unidimensionality was tested through a Principal 
Component Analysis (PCA) of the residuals (Smith et al., 
2006). This test defines two subsets of items, those posi-
tively and those negatively correlated with the first residual 
factor, and the difference in these estimates for each person 
are compared with a t test. The percentage of significant t 
tests should not exceed 5% (Tennant & Conaghan, 2007).
Response dependency was assessed through the residual 
correlation index and a correlation of >0.30 was taken as 
an indication of local dependency (Forjaz et  al., 2012). 
Category structure was explored through category prob-
ability curves, and in case of disordered thresholds, items 
were rescored by collapsing adjacent categories. Scale tar-
geting was assessed through visual inspection of the per-
son–item map, showing the distribution of persons and 
items along the construct.
DIF examines whether different groups within the sam-
ple, despite of equal levels of the characteristic being meas-
ured, respond in a different manner to an individual item 
(Tennant & Pallant, 2007). We studied DIF for age (<65 
vs ≥65 years, which was the median value in our sample), 
sex, and educational level (primary school or less vs more 
than primary school). DIF analysis was performed through 
an analysis of variance (ANOVA) with Bonferroni cor-
rection. In case DIF was identified, this was further ana-
lyzed through a top-down purification approach. In this 
approach, items are divided into two groups, according to 
the presence of absence of DIF, and these are applied as 
Table 1. Characteristics of the Study Sample (n = 1,400) and 
Rasch Analysis Subsample (n = 300)
Total sample Subsample
 N (%)  N (%)
Characteristic (range)  Mean ± SD  Mean ± SD
Sex
 Men 625 (44.64) 132 (44.00)
 Women 775 (55.36) 168 (56.00)
Age (years) 65.50 ± 10.40 64.96 ± 10.27
Education
 Less than primary 480 (34.30) 98 (32.67)
 Primary 313 (22.40) 77 (25.67)
 Secondary 298 (21.30) 61 (20.33)
 University 309 (22.10) 64 (21.33)
Living area
 <10.000 inhabitants 315 (22.50) 70 (23.33)
  10.000–100.000 
inhabitants
502 (35.90) 103 (34.33)
  100.000–500.000 
inhabitants
385 (27.50) 90 (30.33)
 >500.000 inhabitants 198 (14.10) 37 (12.33)
Marital status
 Single 75 (5.36) 17 (5.67)
 Married/living with partner 1014 (72.43) 225 (75.00)
 Widowed 244 (17.43) 44 (14.67)
 Divorced/separated 67 (4.80) 14 (4.67)
CES-Da
 Depression 297 (21.21) 78 (26.00)
 No depression 797 (56.93) 160 (53.33)
 Missing 306 (21.86) 62 (20.67)
PWI (0–100) 74.94 ± 11.09 73.34 ± 12.52
Satisfaction with health 
(0–10)
7.19 ± 3.92 6.84 ± 1.91
Physical functioning (24–96) 91.06 ± 9.56 90.65 ± 10.10
Number of self-reported 
conditions (0–21)
2.50 ± 2.25 2.61 ± 2.29
DBMA raw score (0–105) 5.29 ± 6.39 5.36 ± 6.19
Note: CES-D  =  Center for Epidemiological Studies-Depression scale; 
DBMA = Disease Burden Morbidity Assessment; PWI = Personal Wellbeing 
Index; SD = standard deviation.
aCutoff point: 3 out of 10.
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two testlets (or superitems). If the superitem formed by the 
items with DIF does not present DIF, then DIF is considered 
to cancel out (Tennant, Penta, et al., 2004).
Once fit to the Rasch model was achieved, disease bur-
den scores of the total sample were used to calculate a lin-
ear measure, on a logit scale, which was converted into a 
0–47 range through a linear transformation. In order to 
compare the subsample of 300 and the rest of the sample 
(n = 1,100), a paired-sample t test was done, comparing the 
logit estimation of the two samples (300 vs 1,100) for each 
raw score. Anchor values of the sample of 300 were used to 
fix item estimations of the other sample. In addition, a DIF 
analysis with the sample as a factor was performed.
Psychometric attributes of the linear measure according 
to the classical test theory were analyzed using Stata 12 ver-
sion for Windows: mean-to-median differences (criterion, 
<10%), floor and ceiling effects (<15%), and skewness (−1 
to 1) were calculated for acceptability (Virués-Ortega et al., 
2010). Construct validity was assessed through known-
groups validity for sex and age (<65 vs  ≥  65  years) and 
convergent validity with other health outcomes. We hypoth-
esized to find higher disease burden scores for women 
(Barnett et al., 2012) and in the highest age group (Global 
Burden of Disease Study 2013 Collaborators, 2015), which 
was studied with a Wilcoxon rank-sum test due to the non-
normal distribution of the linear measure. For convergent 
validity, we calculated Spearman’s rank correlations with 
physical functioning, depression (CES-D total score), QoL 
(PWI), and perceived health (PWI item 2: personal health). 
Moderate to high correlations (r  >  0.30) were expected 
(Cohen, 1988).
We performed a relative precision analysis in order to 
assess how much more or less precise the Rasch-based 
score is relative to the raw summative-based score in distin-
guishing groups expected to differ (Las Hayas et al., 2011). 
This was done for sex and age groups (<65 vs ≥ 65 years). 
Relative precision was calculated as the ratio of pairwise 
Z statistics (the linear measure Z statistic divided by the 
raw score Z statistic) (Sakthong, Charoenvisuthiwongs, & 
Shabunthom, 2008), and a bootstrap method was applied 
in order to obtain confidence intervals (CIs) for relative 
precision statistics (Fitzpatrick et al., 2004). Rasch analysis 
takes into account observations with missing values when 
calculating the linear measure. In order to be able to calcu-
late the relative precision, the studied sample sizes should 
be equal, thus observations with missing values were 
excluded in the latter analysis.
Results
Rasch Analysis
The initial analysis, with the whole study sample, displayed 
poor fit to the Rasch model (Table 2). After selecting a sub-
sample of 300, the fit indices improved, but still did not 
meet the fit criteria. Category probability curves showed 
disordered thresholds, so items were rescored to two (two 
items), three (13 items), four (five items), or five catego-
ries (one item) (Table  3). After this, the DBMA showed 
an acceptable fit to the Rasch model (Table 2). Individual 
item and person fit residuals were within the −2.5 to +2.5 
range, with nonsignificant chi-squares (Table 3). However, 
PSI remained low, 0.272. When repeating this estimation 
in RUMM2020, the PSI improved to 0.637. In the PCA 
of the residuals, 0.72% of tests were outside the previ-
ously set range, indicating unidimensionality. All items 
were locally independent, with a residual correlation index 
ranging 0.000–0.188. No DIF was found for age or educa-
tional level. Four items showed DIF by sex of small mag-
nitude (<0.5 logits): item 1 (hypertension), 14 (anxiety), 
17 (osteoporosis), and 21 (urinary tract problems). In the 
top-down purification approach, this DIF was no longer 
present. The person–item threshold distribution (Figure 1) 
showed a floor effect and no persons represented the scale’s 
higher levels of disease burden. Also, there were very 
few persons located around the highest point of the test 
information curve.
DBMA scores of the total sample were converted into a 
linear measure from 0 to 47 (see Supplementary Material). 
When comparing the subsample of 300 and the rest of 
the sample, no significant differences between the estima-
tions were found (difference = 0.259 logits, t test = 1.226, 
p value = .226, and no DIF was observed by sample.
Classic Psychometric Analysis of the Linear 
Measure
Mean score of the linear measure was 7.36 (SD = 5.01), 
median score 7.44, with a mean–median difference of 
0.17%. Floor effect for the total scale was 18.11%, with no 
ceiling effect, and skewness was 0.046. The linear measure 
presented a correlation of −0.48 with physical functioning, 
−0.47 with perceived health, 0.32 with depression (CES-
D), and −0.24 with the PWI (p < .001). Women scored 
significantly higher than men, with mean scores of 8.14 
(SD = 5.15) and 6.40 (SD = 4.65), respectively (p < .001), 
and scores increased with age: mean score among persons 
<65 years was 5.93 (SD = 4.76) versus a mean score of 8.77 
(SD = 4.84) in persons aged ≥65 years (p < .001). The results 
of the relative precision analysis are shown in Table 4. The 
ability to discriminate between age groups increased by 9% 
when using the linear measure versus the raw score (95% 
CI: 1.03–1.17), but precision decreased 4% for age groups, 
although this difference was not statistically significant 
(95% CI: 0.86–1.05).
Discussion
This study analyzed the measurement properties of the 
DMBA according to the Rasch model. Rasch analysis 
provided knowledge of DBMA psychometric attributes 
that were not previously known. Test of fit to the Rasch 
model was satisfactory after rescoring response options, 
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with all items showing a good fit, and the scale was uni-
dimensional. The residual correlation index did not iden-
tify response dependency, meaning that there were no 
items linked in such way that the response to one item 
would determine the response to another. Furthermore, 
Rasch analysis provided a linear measure, which allows 
calculation of change scores and, given a normal distri-
bution, the use of parametric statistics (Hobart, Cano, 
Zajicek, & Thompson, 2007; Tennant, McKenna, & 
Hagell, 2004).
In order to achieve an adequate fit to the Rasch model, 
items needed to be rescored. This might have been due to 
too many response categories, which could have prevented 
people from making fine distinctions between rating scale 
steps. In most cases, response options were reduced to three 
categories. This reduction in response categories does not 
Table 2. Global Fit to the Rasch Model of the DBMA Using the Total Sample (n = 1,400), After Selecting a Subsample (n = 300) 
and After Rescoring the Response Scale
Standard Total sample Subsample After rescoring
Item fit residual Mean 0 −2.90 −1.12 −0.68
SD 1 1.83 0.77 0.71
Person fit residual Mean 0 −0.48 −0.42 −0.28
SD 1 0.59 0.58 0.55
Item–trait interaction χ2 Low 316.33 165.14 154.43
Prob. NS <.001 .89 .32
PSI >0.70 0.07 0.14 0.27
Unidimensionality Significant t tests (%) <5 0.72 2.00 2.00
Note: DBMA = Disease Burden Morbidity Assessment; NS = nonsignificant; Prob. = probability; PSI = Person Separation Index; SD = standard deviation. Item 
fit residual refers to the difference between the data observed and the expected values at item level. Person fit refers to the difference between the data observed 
and the expected values at person level. Item–trait interaction is a chi-square value and probability resulting from the comparison between the expected and the 
mean observed score for groups of people with similar ability estimates. PSI is a reliability measure. Unidimensionality refers to the existence of one measurement 
construct (dimension) underlying the set of items.
Table 3. Threshold Ordering of Polytomous Items and Individual Item Fit to the Rasch Model After Rescoring (n = 300)
Original categories
Individual item fit to the Rasch model0 1 2 3 4 5
Item Rescored categories Location SE Residual χ2 Prob.
Osteoarthritis 0 1 1 1 2 3 −1.914 0.093 −2.020 14.737 .040
Rheumatoid arthritis 0 1 1 1 2 3 −1.514 0.108 −1.749 5.988 .541
Chronic back pain 0 1 1 1 1 2 −1.392 0.130 −0.707 10.910 .143
Depression 0 1 1 1 1 2 −1.161 0.140 −0.996 7.631 .366
Circulation problems/intermittent claudication 0 1 1 1 2 3 −0.965 0.134 −1.698 5.237 .631
Hypertension 0 1 2 2 3 4 −0.934 0.088 −0.515 16.122 .024
Anxiety 0 1 1 1 1 2 −0.858 0.160 −1.474 7.290 .399
Osteoporosis 0 1 1 1 1 2 −0.644 0.162 −1.271 3.796 .803
Cancer 0 1 1 1 2 3 −0.515 0.160 0.068 8.254 .311
Diabetes 0 1 1 1 1 2 −0.371 0.174 −0.637 6.877 .442
Heart failure 0 1 1 1 1 2 −0.331 0.196 −0.055 8.192 .316
Urinary tract problems (prostate, bladder) 0 1 1 1 2 3 −0.219 0.147 −0.436 6.327 .502
COPD/emphysema 0 1 1 1 1 2 −0.137 0.222 −0.162 5.471 .603
Cerebral embolism/stroke 0 1 1 1 1 1 0.296 0.353 0.171 10.195 .178
Memory disorders 0 1 1 1 1 1 0.310 0.355 −0.424 5.818 .561
Gastric/duodenal ulcer 0 1 1 1 1 2 1.081 0.199 0.849 9.992 .189
Kidney disease 0 1 1 1 1 2 1.190 0.218 −0.444 7.298 .399
Asthma 0 1 1 1 1 2 1.578 0.274 −1.258 5.272 .627
Myocardial infarction 0 1 1 1 1 2 1.685 0.296 −0.340 2.781 .904
Angina 0 1 1 1 1 2 2.039 0.473 −0.312 4.173 .760
Parkinson’s disease 0 1 1 2 2 2 2.776 0.924 −0.912 2.071 .956
Note: COPD = chronic obstructive pulmonary disease; Prob. = probability; SE = standard error. Items are ordered by increasing difficulty (mean location of 
thresholds).
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require changing the original questionnaire. Instead, it 
may be performed when calculating the total scores, thus 
avoiding using different response categories that could 
be confusing to the respondent. It would be interesting 
to study whether simplifying the questionnaire, by reduc-
ing the response categories in the same way for all items, 
would improve the psychometric properties of the DBMA. 
However, this might reduce the scale precision.
Some items displayed DIF by sex, indicating that men 
and women, despite having the same level of burden caused 
by hypertension, anxiety, osteoporosis, or urinary tract 
problems, answered differently to these items. A very strict 
approach would have been to delete these items; however, 
this would have compromised the clinical applicability of 
the scale. Another possibility would be to split the items 
and get different calibrations for men and women (Tennant 
& Conaghan, 2007). This would make the scale more diffi-
cult to score, which, nonetheless, is justifiable if DIF results 
are replicated in further studies. DIF was no longer present 
in the top-down purification analysis, meaning that if DIF 
favors men for one item, to balance women are favored 
for another item. So, for the moment, and taking into con-
sideration that differences were of small magnitude, we 
decided to be conservative and avoid scale modifications 
due to DIF. We do not expect DIF to have influenced the 
sex differences found in this study, since DIF refers to group 
differences at the same construct level.
The high floor effect (and as a consequence, the asym-
metrical person–item threshold distribution) represents 
cases in which participants reported not having certain 
conditions. This implies that the floor effect can actually 
be regarded as an indicator of how “healthy” the studied 
population is. Also, there were very few persons located 
near the highest point of the test information curve, which 
represents the location where the test is the most power-
ful in the sense of measurement precision. These data sug-
gest that the test performance would probably improve in 
a hospital-based sample, with a higher proportion of mul-
timorbid patients and therefore less floor effects and better 
scale targeting; thus, more research is needed.
We found a low reliability in RUMM2030 and although 
the PSI value improved when using RUMM2020, it still 
did not fit the criterion. This effect is probably due to the 
design of the DBMA, in which disease burden is rated for 
single diseases. Experiencing disease burden from one dis-
ease does not imply that a person should have the other 
20 conditions as well, which makes items in this scale less 
related to each other than in other scales. Nevertheless, hav-
ing comorbid conditions does increase the disease burden 
experienced from a specific disease (Gadermann, Alonso, 
Vilagut, Zaslavsky, & Kessler, 2012; Moussavi et al., 2007), 
which might have caused that PSI in RUMM2020, less 
influenced by floor effects than in RUMM2030, was closer 
to the criterion of >0.70. This could also make us expect 
the PSI to be higher in a sample with more multimorbidity. 
Low PSIs were also found in other widely used scales, such 
as the EQ-5D-3D (Pickard, De Leon, Kohlmann, Cella, & 
Rosenbloom, 2007).
Our study showed moderate correlations between the 
linear measure and physical functioning, perceived health, 
and depression and a weak correlation with QoL. Bayliss 
and colleagues (2005) reported high correlations with 
physical functioning and perceived health (−0.63 and 0.60, 
respectively) and a weak correlation (−0.29) with depres-
sion. The higher correlations with the first two outcomes, 
in comparison to our results, could be due to the fact that 
Bayliss’ study population was older, which resulted in a 
higher prevalence of chronic conditions. The floor effect in 
our “healthy” population might have attenuated the rela-
tion between the DBMA and these outcomes. We found a 
slightly higher correlation with depression than Bayliss and 
Table 4. Relative Precision of the Linear Measure in Comparison to the Raw Summative DBMA Score (n = 1,277)
Scoring method Patient groups Mean (SE) Mean difference (SE) Z statistic RP 95% CI
Raw score <65 years 3.81 (0.20) 3.02 (0.35) −9.89 1.00
≥65 years 6.83 (0.28)
Linear measure <65 years 5.95 (0.19) 2.98 (0.26) −10.77 1.09 1.03–1.17
≥65 years 8.92 (0.19)
Raw score Men 3.88 (0.19) 2.59 (0.35) −6.61 1.00
Women 6.47 (0.28)
Linear measure Men 6.43 (0.19) 1.78 (0.27) −6.33 0.96 0.86–1.05
Women 8.21 (0.19)
Note: CI = confidence interval; DBMA = Disease Burden Morbidity Assessment; RP = relative precision; SE = standard error.
Figure  1. Person–item distribution and test information curve: final 
Rasch analysis of the Disease Burden Morbidity Assessment (DBMA).AQ7
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colleagues, which can be ascribed to the fact that, unlike 
Bayliss and colleagues, we did include depression in the list 
of conditions used in the DBMA. Depression is a condition 
with a high prevalence and an important cause of disability 
(Ferrari et  al., 2013; Moussavi et  al., 2007). The inverse 
effect also exists: disability itself is an important predictor 
of depression (Bacon et  al., 2016). Therefore, we argued 
that not including depression in the DBMA could underes-
timate disease burden scores. The relative precision analysis 
displayed some gain in precision in discriminating between 
age groups but when discriminating between sex groups, 
no difference was found with the original scale. These data 
suggest that the linear measure is at least as valid as the raw 
summative score concerning discriminant validity.
Some limitations must be acknowledged. We could not 
compare the outcomes of the DBMA with a “gold stand-
ard,” because no other measures of multimorbidity or dis-
ease burden were included in the ELES-PS study. Secondly, 
as mentioned above, we validated a disease burden assess-
ment instrument in a sample with quite a high health status, 
and little multimorbidity and disease burden. The studied 
population consisted of community-dwelling older adults, 
which means that institutionalized persons, with probably 
more multimorbidity, were not included. Also, only persons 
with household telephone lines were selected. The propor-
tion of persons aged 50 years and older in Spain with tel-
ephone lines is estimated to be at least 92% (Rodríguez 
Laso et al., 2013), but it is possible that people that do not 
have a telephone line have lower incomes, which is known 
to be related to lower health status (Katz & Calasanti, 
2015). Moreover, the persons that refused to participate 
in the CAPI interview, the questionnaire that contained 
the DBMA, were of higher age and reported lower per-
ceived health than the respondents who did answer this 
questionnaire (Rodríguez Laso et  al., 2013). Due to the 
relatively high health status, we found a very low PSI, high 
floor effects, and asymmetrical person–item threshold dis-
tribution. A  third limitation was that, like other authors 
(Bayliss et  al., 2009; Hudon, Fortin, Poitras, & Almirall, 
2012; Poitras et al., 2012), we adapted the list of conditions 
included in the DBMA, which hinders comparisons with 
other studies. Further research should include the develop-
ment of a standard list of conditions.
In summary, despite some limitations such as reliability 
below the expected and insufficient scale targeting, sup-
port was found for the validity of the DBMA as a patient-
reported health outcome for measuring disease burden 
caused by 21 common chronic diseases in older adults. Its 
linear measure is related to patient-centered outcomes such 
as QoL and permits the calculation of change scores, mak-
ing it potentially useful for the implementation of strategies 
to improve QoL and functional status among comorbid 
patients. Persons with multimorbidity are progressively 
becoming more common in our health care systems, and 
it is important to assess the impact that patients experi-
ence because of their multimorbidity. The DBMA measures 
the burden of multimorbidity, by asking the respondent to 
rate the impact of diseases on what is most important to 
patients themselves: their everyday life.
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